repaglinide	0	1.7143	4	Be aware that, if metformin is contraindicated or not tolerated, repaglinide is both clinically effective and cost effective in adults with type 2 diabetes	However, discuss with any person for whom repaglinide is being considered, that there is no licensed non-metformin-based combination containing repaglinide that can be offered at first intensification.	Be aware that, if metformin is contraindicated or not tolerated, repaglinide is both clinically effective and cost effective in adults with type 2 diabetes	However, discuss with any person for whom repaglinide is being considered, that there is no licensed non-metformin-based combination containing repaglinide that can be offered at first intensification.	
mmhg	0	1.6597	6	Last updated May 2017 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Last updated May 2017 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage.	Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	
mmol	0	1.5822	7	Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	HbA1c is 75 mmol mol  percent or higher), administered either: separately or as a pre-mixed (biphasic) human insulin preparation.	Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	HbA1c is 75 mmol mol  percent or higher), administered either: separately or as a pre-mixed (biphasic) human insulin preparation.	For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol ( percent)	For adults on a drug associated with hypoglycaemia, support the person to aim for an HbA1c level of 53 mmol mol ( percent).	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	
mol	1	1.5822	12	Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	HbA1c is 75 mmol mol  percent or higher), administered either: separately or as a pre-mixed (biphasic) human insulin preparation.	Refer to an ophthalmologist in accordance with the National Screening	Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	HbA1c is 75 mmol mol  percent or higher), administered either: separately or as a pre-mixed (biphasic) human insulin preparation.	Refer to an ophthalmologist in accordance with the National Screening	For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol ( percent)	For adults on a drug associated with hypoglycaemia, support the person to aim for an HbA1c level of 53 mmol mol ( percent).	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	Depending on the findings, follow structured eye screening by: routine review in 1 year or earlier review or referral to an ophthalmologist.	Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment.	Arrange rapid review by an ophthalmologist for new vessel formation.	
percent	0	1.5822	10	Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).	HbA1c is 75 mmol mol  percent or higher), administered either: separately or as a pre-mixed (biphasic) human insulin preparation.	Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).	HbA1c is 75 mmol mol  percent or higher), administered either: separately or as a pre-mixed (biphasic) human insulin preparation.	For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent	For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol ( percent)	For adults on a drug associated with hypoglycaemia, support the person to aim for an HbA1c level of 53 mmol mol ( percent).	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	
non-insulin	0	1.5	3	Treatment with a single non-insulin blood glucose lowering therapy (monotherapy)	Treatment with 2 non-insulin blood glucose lowering therapies in combination (dual therapy)	Treatment with either 3 non-insulin blood glucose lowering therapies in combination (triple therapy) or any treatment combination containing insulin	
preparations	1	1.5	1	Consider pre-mixed (biphasic) preparations that include short-acting insulin analogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals.	
smoking	1	1.5	1	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	
treatment(s)	1	1.5	2	Base the choice of drug treatment(s) on: the effectiveness of the drug treatment(s) in terms of metabolic response	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	
pressure	0	1.4621	17	Blood pressure management	Last updated May 2017 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic)	If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist).	Monitor the blood pressure of a person who has attained and consistently remained at his or her blood pressure target every 4–6 months	Blood pressure management	Last updated May 2017 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic)	If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist).	Monitor the blood pressure of a person who has attained and consistently remained at his or her blood pressure target every 4–6 months	Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease	For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used.	Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage.	Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Check for possible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure.	
education	1	1.4425	14	Patient education	It is delivered by trained educators who have an understanding of educational theory appropriate to the age and needs of the person, and who are trained and competent to deliver the principles and content of the programme.	Offer group education programmes as the preferred option	Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area.	Patient education	It is delivered by trained educators who have an understanding of educational theory appropriate to the age and needs of the person, and who are trained and competent to deliver the principles and content of the programme.	Offer group education programmes as the preferred option	Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area.	Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with	Explain to people and their carers that structured education is an integral part of diabetes care.	Ensure that any structured education programme for adults with type 2 diabetes includes the following components:	Ensure the patient-education programme provides the necessary resources to support the educators, and that educators are properly trained and given time to develop and maintain their skills.	Provide an alternative of equal standard for a person unable or unwilling to participate in group education.	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	
failure	1	1.4383	8	Pioglitazone is associated with an increased risk of heart failure, bladder cancer and bone fracture	Pioglitazone is associated with an increased risk of heart failure, bladder cancer and bone fracture	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Pioglitazone is associated with an increased risk of heart failure, bladder cancer and bone fracture	Pioglitazone is associated with an increased risk of heart failure, bladder cancer and bone fracture	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure	It advises that if the combination is used, people should be observed for signs and symptoms of heart failure, weight gain, and oedema	
heart	1	1.4383	6	Pioglitazone is associated with an increased risk of heart failure, bladder cancer and bone fracture	Pioglitazone is associated with an increased risk of heart failure, bladder cancer and bone fracture	Pioglitazone is associated with an increased risk of heart failure, bladder cancer and bone fracture	Pioglitazone is associated with an increased risk of heart failure, bladder cancer and bone fracture	In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure	It advises that if the combination is used, people should be observed for signs and symptoms of heart failure, weight gain, and oedema	
factors	0	1.3683	5	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options.	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	
disease	1	1.362	10	Diabetic kidney disease	Eye disease	Diabetic kidney disease	Eye disease	Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease	Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease.	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	For guidance on managing kidney disease in adults with type 2 diabetes, see the	NICE guideline on chronic kidney disease in adults.	Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options.	
neuropathy	0	1.36	8	Painful diabetic neuropathy	Painful diabetic neuropathy	For guidance on managing painful diabetic peripheral neuropathy in adults with type 2 diabetes, see the NICE guideline on neuropathic pain in adults.	Autonomic neuropathy	Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015	When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension.	Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems.	In managing autonomic neuropathy symptoms, include specific interventions indicated by the manifestations (for example, for abnormal sweating or nocturnal diarrhoea).	
age	1	1.3333	69	It is delivered by trained educators who have an understanding of educational theory appropriate to the age and needs of the person, and who are trained and competent to deliver the principles and content of the programme.	Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight.	Remember that lesser degrees of weight loss may still be of benefit, and that larger degrees of weight loss in the longer term will have advantageous metabolic impact.	Discourage the use of foods marketed specifically for people with diabetes.	Blood pressure management	Last updated May 2017 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Blood glucose management	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	Use mydriasis with tropicamide when photographing the retina, after prior informed agreement following discussion of the advantages and disadvantages.	Last updated May 2017 circinate or group of exudates within the macula (the macula is defined here as a circle centred on the fovea, with a diameter the distance between the temporal border of the optic disc and the fovea) any microaneurysm or haemorrhage within 1 disc diameter of the centre of the fovea, only if associated with deterioration of best visual acuity to 6 12 or worse. referable pre-proliferative retinopathy (if cotton wool spots are present, look carefully for the following features, but cotton wool spots themselves do not define pre-proliferative retinopathy): any venous beading any venous reduplication any intraretinal microvascular abnormalities multiple deep, round or blot haemorrhages. any large, sudden unexplained drop in visual acuity 2009, amended 2015	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2014) notes that domperidone is associated with a small increased risk of serious cardiac side effects	It is delivered by trained educators who have an understanding of educational theory appropriate to the age and needs of the person, and who are trained and competent to deliver the principles and content of the programme.	Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight.	Remember that lesser degrees of weight loss may still be of benefit, and that larger degrees of weight loss in the longer term will have advantageous metabolic impact.	Discourage the use of foods marketed specifically for people with diabetes.	Blood pressure management	Last updated May 2017 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Blood glucose management	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	Use mydriasis with tropicamide when photographing the retina, after prior informed agreement following discussion of the advantages and disadvantages.	Last updated May 2017 circinate or group of exudates within the macula (the macula is defined here as a circle centred on the fovea, with a diameter the distance between the temporal border of the optic disc and the fovea) any microaneurysm or haemorrhage within 1 disc diameter of the centre of the fovea, only if associated with deterioration of best visual acuity to 6 12 or worse. referable pre-proliferative retinopathy (if cotton wool spots are present, look carefully for the following features, but cotton wool spots themselves do not define pre-proliferative retinopathy): any venous beading any venous reduplication any intraretinal microvascular abnormalities multiple deep, round or blot haemorrhages. any large, sudden unexplained drop in visual acuity 2009, amended 2015	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2014) notes that domperidone is associated with a small increased risk of serious cardiac side effects	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	It has specific aims and learning objectives, and supports the person and their family members and carers in developing attitudes, beliefs, knowledge and skills to self-manage diabetes.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Encourage high-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Encourage them to achieve the target and maintain it unless any resulting adverse effects (including hypoglycaemia), or their efforts to achieve their target, impair their quality of life.	For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol ( percent)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Following discussion, refer men with type 2 diabetes to a service offering other medical, surgical or psychological management of erectile dysfunction if treatment (including a phosphodiesterase-5 inhibitor, as appropriate) has been unsuccessful.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2016) warned that serious, life-threatening, and fatal cases of diabetic ketoacidosis have been reported rarely in people taking an SGLT-2 inhibitor (a substantial proportion of the cases concerned off-label use in people with type 1 diabetes, which is not recommended)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	
assessment	0	1.3333	2	If adults with type 2 diabetes are self-monitoring their blood glucose levels, carry out a structured assessment at least annually	The assessment should include: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used.	
bmi	1	1.3333	1	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	
cases	0	1.3333	5	In several cases, blood glucose levels were only moderately elevated	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	In several cases, blood glucose levels were only moderately elevated	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2016) warned that serious, life-threatening, and fatal cases of diabetic ketoacidosis have been reported rarely in people taking an SGLT-2 inhibitor (a substantial proportion of the cases concerned off-label use in people with type 1 diabetes, which is not recommended)	
characteristics	0	1.3333	4	MHRA guidance and summaries of product characteristics	MHRA guidance and summaries of product characteristics	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	
delivery	1	1.3333	3	Insulin delivery	Insulin delivery	For guidance on insulin delivery for adults with type 2 diabetes, see the insulin delivery section in the NICE guideline on type 1 diabetes.	
details	0	1.3333	6	The full guideline gives details of the methods and the evidence used to develop the guidance.	See about this guideline for details.	The full guideline gives details of the methods and the evidence used to develop the guidance.	See about this guideline for details.	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	
educators	0	1.3333	3	It is delivered by trained educators who have an understanding of educational theory appropriate to the age and needs of the person, and who are trained and competent to deliver the principles and content of the programme.	It is delivered by trained educators who have an understanding of educational theory appropriate to the age and needs of the person, and who are trained and competent to deliver the principles and content of the programme.	Ensure the patient-education programme provides the necessary resources to support the educators, and that educators are properly trained and given time to develop and maintain their skills.	
efficacy	0	1.3333	2	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	
egfr	1	1.3333	4	Stop metformin if the eGFR is below 30 ml minute m2.	Stop metformin if the eGFR is below 30 ml minute m2.	In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute m2:	Prescribe metformin with caution for those at risk of a sudden deterioration in kidney function and those at risk of eGFR falling below 45 ml minute m2.	
foot	1	1.3333	3	Diabetic foot problems	Diabetic foot problems	For guidance on preventing and managing foot problems in adults with type 2 diabetes, see the NICE guideline on diabetic foot problems.	
individuals	0	1.3333	2	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	
intervals	0	1.3333	1	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	
ketoacidosis	0	1.3333	4	Last updated May 2017 hepatic impairment diabetic ketoacidosis current, or a history of, bladder cancer uninvestigated macroscopic haematuria.	Last updated May 2017 hepatic impairment diabetic ketoacidosis current, or a history of, bladder cancer uninvestigated macroscopic haematuria.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2016) warned that serious, life-threatening, and fatal cases of diabetic ketoacidosis have been reported rarely in people taking an SGLT-2 inhibitor (a substantial proportion of the cases concerned off-label use in people with type 1 diabetes, which is not recommended)	The MHRA advised that healthcare professionals should test for raised ketones in people with ketoacidosis symptoms who are receiving an SGLT-2 inhibitor, even if their plasma glucose levels are near-normal.	
kg	1	1.3333	1	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	
manufacturers	0	1.3333	2	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	
measurement	0	1.3333	4	Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage.	HbA1c measurement and targets	Measurement	Investigate unexplained discrepancies between HbA1c and other glucose measurements	
minute	1	1.3333	4	Stop metformin if the eGFR is below 30 ml minute m2.	Stop metformin if the eGFR is below 30 ml minute m2.	In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute m2:	Prescribe metformin with caution for those at risk of a sudden deterioration in kidney function and those at risk of eGFR falling below 45 ml minute m2.	
ml	1	1.3333	4	Stop metformin if the eGFR is below 30 ml minute m2.	Stop metformin if the eGFR is below 30 ml minute m2.	In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute m2:	Prescribe metformin with caution for those at risk of a sudden deterioration in kidney function and those at risk of eGFR falling below 45 ml minute m2.	
patients	1	1.3333	5	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	
product	0	1.3333	16	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2014) notes that domperidone is associated with a small increased risk of serious cardiac side effects	MHRA guidance and summaries of product characteristics	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2014) notes that domperidone is associated with a small increased risk of serious cardiac side effects	MHRA guidance and summaries of product characteristics	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Encourage high-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids.	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2016) warned that serious, life-threatening, and fatal cases of diabetic ketoacidosis have been reported rarely in people taking an SGLT-2 inhibitor (a substantial proportion of the cases concerned off-label use in people with type 1 diabetes, which is not recommended)	The recommendations in this guideline also apply to any current and future biosimilar product(s) of insulin glargine that have an appropriate marketing authorisation that allows the use of the biosimilar(s) in the same indication.	
programmes	0	1.3333	7	Offer group education programmes as the preferred option	Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area.	Perform visual acuity testing as a routine part of eye screening programmes.	Offer group education programmes as the preferred option	Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area.	Perform visual acuity testing as a routine part of eye screening programmes.	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	
recent-onset	0	1.3333	1	For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	
screening	1	1.3333	11	Perform screening as soon as possible and no later than 3 months from referral	Arrange repeat structured eye screening annually. 2009, amended 2016	Perform visual acuity testing as a routine part of eye screening programmes.	Refer to an ophthalmologist in accordance with the National Screening	Perform screening as soon as possible and no later than 3 months from referral	Arrange repeat structured eye screening annually. 2009, amended 2016	Perform visual acuity testing as a routine part of eye screening programmes.	Refer to an ophthalmologist in accordance with the National Screening	On diagnosis, GPs should immediately refer adults with type 2 diabetes to the local eye screening service	Explain the reasons for, and success of, eye screening systems to adults with type 2 diabetes, so that attendance is not reduced by lack of knowledge or fear of outcome.	Depending on the findings, follow structured eye screening by: routine review in 1 year or earlier review or referral to an ophthalmologist.	
sites	1	1.3333	1	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
summaries	0	1.3333	4	MHRA guidance and summaries of product characteristics	MHRA guidance and summaries of product characteristics	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	
surgery	1	1.3333	3	Dietary advice and bariatric surgery	Dietary advice and bariatric surgery	For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	
titration	1	1.3333	1	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
domperidone	1	1.3296	7	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2014) notes that domperidone is associated with a small increased risk of serious cardiac side effects	Domperidone is now contraindicated in certain groups in whom the risk of cardiac effects is higher; its marketing authorisations have also been restricted to its use in the relief of nausea and vomiting only, at the lowest effective dose and for the shortest possible time (usually not more than 1 week): see the	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2014) notes that domperidone is associated with a small increased risk of serious cardiac side effects	Domperidone is now contraindicated in certain groups in whom the risk of cardiac effects is higher; its marketing authorisations have also been restricted to its use in the relief of nausea and vomiting only, at the lowest effective dose and for the shortest possible time (usually not more than 1 week): see the	For adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that: there is not strong evidence that any available antiemetic therapy is effective some people have had benefit with domperidone , erythromycin or metoclopramide . the strongest evidence for effectiveness is for domperidone , but prescribers must	For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance.	The MHRA advises that prescribers should take into account the overall safety profile of domperidone, and in particular its cardiac risk and potential interactions with other medicines (such as erythromycin), if there is a clinical need to use it at doses or durations greater than those authorised	
dysfunction	1	1.3184	6	Erectile dysfunction	Erectile dysfunction	Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review.	Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options.	Consider a phosphodiesterase-5 inhibitor to treat problematic erectile dysfunction in men with type 2 diabetes, initially choosing the drug with the lowest acquisition cost and taking into account any contraindications.	Following discussion, refer men with type 2 diabetes to a service offering other medical, surgical or psychological management of erectile dysfunction if treatment (including a phosphodiesterase-5 inhibitor, as appropriate) has been unsuccessful.	
men	1	1.3184	119	Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight.	Blood pressure management	Add the other drug (that is, the calcium-channel blocker or diuretic) if the target is not reached with dual therapy 2009, amended 2015	Blood glucose management	Last updated May 2017 hepatic impairment diabetic ketoacidosis current, or a history of, bladder cancer uninvestigated macroscopic haematuria.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	Arrange repeat structured eye screening annually. 2009, amended 2016	Use mydriasis with tropicamide when photographing the retina, after prior informed agreement following discussion of the advantages and disadvantages.	Last updated May 2017 circinate or group of exudates within the macula (the macula is defined here as a circle centred on the fovea, with a diameter the distance between the temporal border of the optic disc and the fovea) any microaneurysm or haemorrhage within 1 disc diameter of the centre of the fovea, only if associated with deterioration of best visual acuity to 6 12 or worse. referable pre-proliferative retinopathy (if cotton wool spots are present, look carefully for the following features, but cotton wool spots themselves do not define pre-proliferative retinopathy): any venous beading any venous reduplication any intraretinal microvascular abnormalities multiple deep, round or blot haemorrhages. any large, sudden unexplained drop in visual acuity 2009, amended 2015	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight.	Blood pressure management	Add the other drug (that is, the calcium-channel blocker or diuretic) if the target is not reached with dual therapy 2009, amended 2015	Blood glucose management	Last updated May 2017 hepatic impairment diabetic ketoacidosis current, or a history of, bladder cancer uninvestigated macroscopic haematuria.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	Arrange repeat structured eye screening annually. 2009, amended 2016	Use mydriasis with tropicamide when photographing the retina, after prior informed agreement following discussion of the advantages and disadvantages.	Last updated May 2017 circinate or group of exudates within the macula (the macula is defined here as a circle centred on the fovea, with a diameter the distance between the temporal border of the optic disc and the fovea) any microaneurysm or haemorrhage within 1 disc diameter of the centre of the fovea, only if associated with deterioration of best visual acuity to 6 12 or worse. referable pre-proliferative retinopathy (if cotton wool spots are present, look carefully for the following features, but cotton wool spots themselves do not define pre-proliferative retinopathy): any venous beading any venous reduplication any intraretinal microvascular abnormalities multiple deep, round or blot haemorrhages. any large, sudden unexplained drop in visual acuity 2009, amended 2015	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Last updated May 2017 1 Recommendations	The wording used in the recommendations in this guideline (for example, words such as 'offer' and 'consider') denotes the certainty with which the recommendation is made (the strength of the recommendation)	Initial drug treatment	Treatment with a single non-insulin blood glucose lowering therapy (monotherapy)	First intensification of drug treatment	Treatment with 2 non-insulin blood glucose lowering therapies in combination (dual therapy)	Second intensification of drug treatment	Treatment with either 3 non-insulin blood glucose lowering therapies in combination (triple therapy) or any treatment combination containing insulin	Take into account any disabilities, including visual impairment, when planning and delivering care for adults with type 2 diabetes.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Last updated May 2017 annual reinforcement and review	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Individualise recommendations for carbohydrate and alcohol intake, and meal patterns	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks.	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used.	Make changes only if there is poor control or if current drug treatment is not appropriate because of microvascular complications or metabolic problems.	Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor	African or Caribbean family origin, or women for whom there is a possibility of becoming pregnant.	The first-line antihypertensive drug treatment for a person of African or	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Check for possible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure.	HbA1c measurement and targets	Measurement	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Investigate unexplained discrepancies between HbA1c and other glucose measurements	Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section )	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	Consider relaxing the target HbA1c level (see recommendations and )	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia.	Review treatment as necessary.	If adults with type 2 diabetes are self-monitoring their blood glucose levels, carry out a structured assessment at least annually	The assessment should include: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used.	Drug treatment	Recommendations in this section that cover dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) mimetics and sulfonylureas refer to each of these groups of drugs at a class level.	For adults with type 2 diabetes, discuss the benefits and risks of drug treatment, and the options available	Base the choice of drug treatment(s) on: the effectiveness of the drug treatment(s) in terms of metabolic response	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Rescue therapy at any phase of treatment	If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations – ) or a sulfonylurea, and review treatment when blood glucose control has been achieved.	Initial drug treatment	Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Treatment with sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some adults with type 2 diabetes if metformin is contraindicated or not tolerated (see NICE's guidance on canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes).	First intensification of drug treatment	In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	Treatment with combinations of medicines including sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Second intensification of drug treatment	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations – ).	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in triple therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Insulin-based treatments	Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance.	Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015	Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015	When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review.	Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options.	Consider a phosphodiesterase-5 inhibitor to treat problematic erectile dysfunction in men with type 2 diabetes, initially choosing the drug with the lowest acquisition cost and taking into account any contraindications.	Following discussion, refer men with type 2 diabetes to a service offering other medical, surgical or psychological management of erectile dysfunction if treatment (including a phosphodiesterase-5 inhibitor, as appropriate) has been unsuccessful.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2016) warned that serious, life-threatening, and fatal cases of diabetic ketoacidosis have been reported rarely in people taking an SGLT-2 inhibitor (a substantial proportion of the cases concerned off-label use in people with type 1 diabetes, which is not recommended)	The recommendations in this guideline also apply to any current and future biosimilar product(s) of insulin glargine that have an appropriate marketing authorisation that allows the use of the biosimilar(s) in the same indication.	Informed consent should be obtained and documented	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	
first-line	0	1.2878	5	If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic)	If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic)	First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor	The first-line antihypertensive drug treatment for a person of African or	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant.	
ophthalmologist	0	1.2878	5	Refer to an ophthalmologist in accordance with the National Screening	Refer to an ophthalmologist in accordance with the National Screening	Depending on the findings, follow structured eye screening by: routine review in 1 year or earlier review or referral to an ophthalmologist.	Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment.	Arrange rapid review by an ophthalmologist for new vessel formation.	
adult	0	1.2858	87	Be aware that, if metformin is contraindicated or not tolerated, repaglinide is both clinically effective and cost effective in adults with type 2 diabetes	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	Take into account any disabilities, including visual impairment, when planning and delivering care for adults with type 2 diabetes.	Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Ensure that any structured education programme for adults with type 2 diabetes includes the following components:	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes	For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks.	Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease	For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used.	Provide lifestyle advice (see section in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease.	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Involve adults with type 2 diabetes in decisions about their individual HbA1c target	Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section )	For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol ( percent)	For adults on a drug associated with hypoglycaemia, support the person to aim for an HbA1c level of 53 mmol mol ( percent).	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia.	Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia	If adults with type 2 diabetes are self-monitoring their blood glucose levels, carry out a structured assessment at least annually	For adults with type 2 diabetes, discuss the benefits and risks of drug treatment, and the options available	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations – ) or a sulfonylurea, and review treatment when blood glucose control has been achieved.	Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes.	Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes.	If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin.	Algorithm for blood glucose lowering therapy in adults with type 2 diabetes	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute m2:	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea.	In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Treatment with sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some adults with type 2 diabetes if metformin is contraindicated or not tolerated (see NICE's guidance on canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes).	In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations – ).	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team .	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance	Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	For guidance on insulin delivery for adults with type 2 diabetes, see the insulin delivery section in the NICE guideline on type 1 diabetes.	Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015	For adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that: there is not strong evidence that any available antiemetic therapy is effective some people have had benefit with domperidone , erythromycin or metoclopramide . the strongest evidence for effectiveness is for domperidone , but prescribers must	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance.	For guidance on managing painful diabetic peripheral neuropathy in adults with type 2 diabetes, see the NICE guideline on neuropathic pain in adults.	Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015	Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015	When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension.	Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	For guidance on preventing and managing foot problems in adults with type 2 diabetes, see the NICE guideline on diabetic foot problems.	For guidance on managing kidney disease in adults with type 2 diabetes, see the	NICE guideline on chronic kidney disease in adults.	On diagnosis, GPs should immediately refer adults with type 2 diabetes to the local eye screening service	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Explain the reasons for, and success of, eye screening systems to adults with type 2 diabetes, so that attendance is not reduced by lack of knowledge or fear of outcome.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Be aware that, if metformin is contraindicated or not tolerated, repaglinide is both clinically effective and cost effective in adults with type 2 diabetes	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	
dipeptidyl	1	1.2844	2	Recommendations in this section that cover dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) mimetics and sulfonylureas refer to each of these groups of drugs at a class level.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea.	
peptidase-4	0	1.2844	2	Recommendations in this section that cover dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) mimetics and sulfonylureas refer to each of these groups of drugs at a class level.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea.	
carers	0	1.2787	4	Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with	Explain to people and their carers that structured education is an integral part of diabetes care.	It has specific aims and learning objectives, and supports the person and their family members and carers in developing attitudes, beliefs, knowledge and skills to self-manage diabetes.	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	
carbohydrate	1	1.2695	4	Encourage high-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids.	Individualise recommendations for carbohydrate and alcohol intake, and meal patterns	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks.	
cost	0	1.2693	5	Be aware that, if metformin is contraindicated or not tolerated, repaglinide is both clinically effective and cost effective in adults with type 2 diabetes	Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia.	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Consider a phosphodiesterase-5 inhibitor to treat problematic erectile dysfunction in men with type 2 diabetes, initially choosing the drug with the lowest acquisition cost and taking into account any contraindications.	Be aware that, if metformin is contraindicated or not tolerated, repaglinide is both clinically effective and cost effective in adults with type 2 diabetes	
intake	0	1.2674	3	Encourage high-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids.	Individualise recommendations for carbohydrate and alcohol intake, and meal patterns	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	
insulin	1	1.2502	34	Offer NPH insulin injected once or twice daily according to need.	HbA1c is 75 mmol mol  percent or higher), administered either: separately or as a pre-mixed (biphasic) human insulin preparation.	HbA1c reached or who cannot use the device needed to inject NPH insulin but who could administer their own insulin safely and accurately if a switch to one of the long-acting insulin analogues was made or	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections.	Insulin delivery	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Offer NPH insulin injected once or twice daily according to need.	HbA1c is 75 mmol mol  percent or higher), administered either: separately or as a pre-mixed (biphasic) human insulin preparation.	HbA1c reached or who cannot use the device needed to inject NPH insulin but who could administer their own insulin safely and accurately if a switch to one of the long-acting insulin analogues was made or	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections.	Insulin delivery	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Treatment with a single non-insulin blood glucose lowering therapy (monotherapy)	Treatment with 2 non-insulin blood glucose lowering therapies in combination (dual therapy)	Treatment with either 3 non-insulin blood glucose lowering therapies in combination (triple therapy) or any treatment combination containing insulin	Reducing the risk of hypoglycaemia should be a particular aim for a person using insulin or an insulin secretagogue.	Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations – ) or a sulfonylurea, and review treatment when blood glucose control has been achieved.	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations – ).	In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team .	Insulin-based treatments	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance	Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:	Consider starting both NPH and short-acting insulin (particularly if the person's	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if: the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs.	Consider pre-mixed (biphasic) preparations that include short-acting insulin analogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals.	Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	For guidance on insulin delivery for adults with type 2 diabetes, see the insulin delivery section in the NICE guideline on type 1 diabetes.	The recommendations in this guideline also apply to any current and future biosimilar product(s) of insulin glargine that have an appropriate marketing authorisation that allows the use of the biosimilar(s) in the same indication.	
sulfonylurea	0	1.2346	9	pioglitazone or a sulfonylurea.	pioglitazone or a sulfonylurea.	Recommendations in this section that cover dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) mimetics and sulfonylureas refer to each of these groups of drugs at a class level.	If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations – ) or a sulfonylurea, and review treatment when blood glucose control has been achieved.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea.	In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	
arrange	1	1.2335	4	Arrange repeat structured eye screening annually. 2009, amended 2016	Arrange repeat structured eye screening annually. 2009, amended 2016	Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment.	Arrange rapid review by an ophthalmologist for new vessel formation.	
beliefs	0	1.2335	2	It has specific aims and learning objectives, and supports the person and their family members and carers in developing attitudes, beliefs, knowledge and skills to self-manage diabetes.	Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life.	
blocker	0	1.2335	8	If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic)	Add the other drug (that is, the calcium-channel blocker or diuretic) if the target is not reached with dual therapy 2009, amended 2015	If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist).	If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic)	Add the other drug (that is, the calcium-channel blocker or diuretic) if the target is not reached with dual therapy 2009, amended 2015	If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist).	Caribbean family origin should be an ACE inhibitor plus either a diuretic or a generic calcium-channel blocker.	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant.	
calcium-channel	0	1.2335	6	If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic)	Add the other drug (that is, the calcium-channel blocker or diuretic) if the target is not reached with dual therapy 2009, amended 2015	If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic)	Add the other drug (that is, the calcium-channel blocker or diuretic) if the target is not reached with dual therapy 2009, amended 2015	Caribbean family origin should be an ACE inhibitor plus either a diuretic or a generic calcium-channel blocker.	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant.	
consistency	0	1.2335	2	It is quality assured, and reviewed by trained, competent, independent assessors who measure it against criteria that ensure consistency.	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks.	
discussion	0	1.2335	5	Use mydriasis with tropicamide when photographing the retina, after prior informed agreement following discussion of the advantages and disadvantages.	Use mydriasis with tropicamide when photographing the retina, after prior informed agreement following discussion of the advantages and disadvantages.	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant.	Following discussion, refer men with type 2 diabetes to a service offering other medical, surgical or psychological management of erectile dysfunction if treatment (including a phosphodiesterase-5 inhibitor, as appropriate) has been unsuccessful.	Discussions should include precautions for driving.	
origin	1	1.2335	2	African or Caribbean family origin, or women for whom there is a possibility of becoming pregnant.	Caribbean family origin should be an ACE inhibitor plus either a diuretic or a generic calcium-channel blocker.	
referral	0	1.2335	5	Perform screening as soon as possible and no later than 3 months from referral	Perform screening as soon as possible and no later than 3 months from referral	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	If gastroparesis is suspected, consider referral to specialist services if: the differential diagnosis is in doubt or persistent or severe vomiting occurs.	Depending on the findings, follow structured eye screening by: routine review in 1 year or earlier review or referral to an ophthalmologist.	
signs	0	1.2335	2	Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015	It advises that if the combination is used, people should be observed for signs and symptoms of heart failure, weight gain, and oedema	
specialist	1	1.2335	4	Seek advice from a team with specialist expertise in diabetes or clinical biochemistry.	Seek advice from a team with specialist expertise in diabetes or clinical biochemistry.	In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team .	If gastroparesis is suspected, consider referral to specialist services if: the differential diagnosis is in doubt or persistent or severe vomiting occurs.	
system	0	1.2335	3	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks.	Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015	Explain the reasons for, and success of, eye screening systems to adults with type 2 diabetes, so that attendance is not reduced by lack of knowledge or fear of outcome.	
women	1	1.2335	2	African or Caribbean family origin, or women for whom there is a possibility of becoming pregnant.	For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy.	
gastroparesis	0	1.2279	6	Gastroparesis	Gastroparesis	Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015	For adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that: there is not strong evidence that any available antiemetic therapy is effective some people have had benefit with domperidone , erythromycin or metoclopramide . the strongest evidence for effectiveness is for domperidone , but prescribers must	For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance.	If gastroparesis is suspected, consider referral to specialist services if: the differential diagnosis is in doubt or persistent or severe vomiting occurs.	
members	0	1.2271	3	Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with	It has specific aims and learning objectives, and supports the person and their family members and carers in developing attitudes, beliefs, knowledge and skills to self-manage diabetes.	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	
diet	1	1.2227	10	Dietary advice and bariatric surgery	Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight.	Dietary advice and bariatric surgery	Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight.	Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life.	Encourage high-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids.	Provide lifestyle advice (diet and exercise) at the same time.	For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol ( percent)	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
months	0	1.2205	10	Monitor the blood pressure of a person who has attained and consistently remained at his or her blood pressure target every 4–6 months	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).	Perform screening as soon as possible and no later than 3 months from referral	Monitor the blood pressure of a person who has attained and consistently remained at his or her blood pressure target every 4–6 months	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).	Perform screening as soon as possible and no later than 3 months from referral	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage.	Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	
services	0	1.2189	2	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	If gastroparesis is suspected, consider referral to specialist services if: the differential diagnosis is in doubt or persistent or severe vomiting occurs.	
standard-release	0	1.2148	3	Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes.	Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes.	If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin.	
dpp-4	1	1.2141	5	Recommendations in this section that cover dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) mimetics and sulfonylureas refer to each of these groups of drugs at a class level.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea.	In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	
foods	0	1.2075	4	Discourage the use of foods marketed specifically for people with diabetes.	Discourage the use of foods marketed specifically for people with diabetes.	Encourage high-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids.	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	
possibility	0	1.2031	5	African or Caribbean family origin, or women for whom there is a possibility of becoming pregnant.	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant.	Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015	Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015	Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems.	
side	1	1.1953	25	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2014) notes that domperidone is associated with a small increased risk of serious cardiac side effects	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2014) notes that domperidone is associated with a small increased risk of serious cardiac side effects	However, discuss with any person for whom repaglinide is being considered, that there is no licensed non-metformin-based combination containing repaglinide that can be offered at first intensification.	The wording used in the recommendations in this guideline (for example, words such as 'offer' and 'consider') denotes the certainty with which the recommendation is made (the strength of the recommendation)	Consider relaxing the target HbA1c level (see recommendations and )	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia.	If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations – ) or a sulfonylurea, and review treatment when blood glucose control has been achieved.	Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes.	If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea.	In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations – ).	Consider starting both NPH and short-acting insulin (particularly if the person's	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if: the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs.	Consider pre-mixed (biphasic) preparations that include short-acting insulin analogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals.	Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance.	If gastroparesis is suspected, consider referral to specialist services if: the differential diagnosis is in doubt or persistent or severe vomiting occurs.	When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension.	Consider a phosphodiesterase-5 inhibitor to treat problematic erectile dysfunction in men with type 2 diabetes, initially choosing the drug with the lowest acquisition cost and taking into account any contraindications.	However, discuss with any person for whom repaglinide is being considered, that there is no licensed non-metformin-based combination containing repaglinide that can be offered at first intensification.	
quality	1	1.1947	8	Last updated May 2017 of the following: quality-controlled plasma glucose profiles total glycated haemoglobin estimation (if abnormal haemoglobins) fructosamine estimation.	Use a quality-assured digital retinal photography programme using appropriately trained staff.	Last updated May 2017 of the following: quality-controlled plasma glucose profiles total glycated haemoglobin estimation (if abnormal haemoglobins) fructosamine estimation.	Use a quality-assured digital retinal photography programme using appropriately trained staff.	It is quality assured, and reviewed by trained, competent, independent assessors who measure it against criteria that ensure consistency.	Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life.	Encourage them to achieve the target and maintain it unless any resulting adverse effects (including hypoglycaemia), or their efforts to achieve their target, impair their quality of life.	The assessment should include: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used.	
problems	0	1.189	6	Diabetic foot problems	Diabetic foot problems	Make changes only if there is poor control or if current drug treatment is not appropriate because of microvascular complications or metabolic problems.	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems.	For guidance on preventing and managing foot problems in adults with type 2 diabetes, see the NICE guideline on diabetic foot problems.	
pregnancy	1	1.1821	2	For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy.	For more information, see the NICE guideline on diabetes in pregnancy.	
dose	0	1.1774	6	Domperidone is now contraindicated in certain groups in whom the risk of cardiac effects is higher; its marketing authorisations have also been restricted to its use in the relief of nausea and vomiting only, at the lowest effective dose and for the shortest possible time (usually not more than 1 week): see the	Domperidone is now contraindicated in certain groups in whom the risk of cardiac effects is higher; its marketing authorisations have also been restricted to its use in the relief of nausea and vomiting only, at the lowest effective dose and for the shortest possible time (usually not more than 1 week): see the	Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes.	In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute m2:	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	The MHRA advises that prescribers should take into account the overall safety profile of domperidone, and in particular its cardiac risk and potential interactions with other medicines (such as erythromycin), if there is a clinical need to use it at doses or durations greater than those authorised	
prescribers	0	1.1765	4	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	For adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that: there is not strong evidence that any available antiemetic therapy is effective some people have had benefit with domperidone , erythromycin or metoclopramide . the strongest evidence for effectiveness is for domperidone , but prescribers must	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	The MHRA advises that prescribers should take into account the overall safety profile of domperidone, and in particular its cardiac risk and potential interactions with other medicines (such as erythromycin), if there is a clinical need to use it at doses or durations greater than those authorised	
risk	1	1.1506	33	When prescribing pioglitazone, exercise particular caution if the person is at high risk of the adverse effects of the drug	Pioglitazone is associated with an increased risk of heart failure, bladder cancer and bone fracture	Last updated May 2017 take into account its safety profile, in particular its cardiac risk and potential interactions with other medicines.	When prescribing pioglitazone, exercise particular caution if the person is at high risk of the adverse effects of the drug	Pioglitazone is associated with an increased risk of heart failure, bladder cancer and bone fracture	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	At the time of publication (March 2017) evidence did not show an increased risk for dapagliflozin and empagliflozin, but the MHRA advised that the risk may be a class effect.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2014) notes that domperidone is associated with a small increased risk of serious cardiac side effects	Domperidone is now contraindicated in certain groups in whom the risk of cardiac effects is higher; its marketing authorisations have also been restricted to its use in the relief of nausea and vomiting only, at the lowest effective dose and for the shortest possible time (usually not more than 1 week): see the	When prescribing pioglitazone, exercise particular caution if the person is at high risk of the adverse effects of the drug	Pioglitazone is associated with an increased risk of heart failure, bladder cancer and bone fracture	Last updated May 2017 take into account its safety profile, in particular its cardiac risk and potential interactions with other medicines.	When prescribing pioglitazone, exercise particular caution if the person is at high risk of the adverse effects of the drug	Pioglitazone is associated with an increased risk of heart failure, bladder cancer and bone fracture	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	At the time of publication (March 2017) evidence did not show an increased risk for dapagliflozin and empagliflozin, but the MHRA advised that the risk may be a class effect.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2014) notes that domperidone is associated with a small increased risk of serious cardiac side effects	Domperidone is now contraindicated in certain groups in whom the risk of cardiac effects is higher; its marketing authorisations have also been restricted to its use in the relief of nausea and vomiting only, at the lowest effective dose and for the shortest possible time (usually not more than 1 week): see the	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	Reducing the risk of hypoglycaemia should be a particular aim for a person using insulin or an insulin secretagogue.	Check for possible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure.	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia	For adults with type 2 diabetes, discuss the benefits and risks of drug treatment, and the options available	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes.	Prescribe metformin with caution for those at risk of a sudden deterioration in kidney function and those at risk of eGFR falling below 45 ml minute m2.	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	The MHRA advises that prescribers should take into account the overall safety profile of domperidone, and in particular its cardiac risk and potential interactions with other medicines (such as erythromycin), if there is a clinical need to use it at doses or durations greater than those authorised	
safety	1	1.1468	6	Last updated May 2017 take into account its safety profile, in particular its cardiac risk and potential interactions with other medicines.	Last updated May 2017 take into account its safety profile, in particular its cardiac risk and potential interactions with other medicines.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	The MHRA advises that prescribers should take into account the overall safety profile of domperidone, and in particular its cardiac risk and potential interactions with other medicines (such as erythromycin), if there is a clinical need to use it at doses or durations greater than those authorised	
hypertension	1	1.1459	3	Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease	Provide lifestyle advice (see section in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood	Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension.	
benefit	0	1.131	10	Remember that lesser degrees of weight loss may still be of benefit, and that larger degrees of weight loss in the longer term will have advantageous metabolic impact.	Remember that lesser degrees of weight loss may still be of benefit, and that larger degrees of weight loss in the longer term will have advantageous metabolic impact.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	The assessment should include: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used.	For adults with type 2 diabetes, discuss the benefits and risks of drug treatment, and the options available	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	For adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that: there is not strong evidence that any available antiemetic therapy is effective some people have had benefit with domperidone , erythromycin or metoclopramide . the strongest evidence for effectiveness is for domperidone , but prescribers must	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	
symptoms	0	1.1223	3	In managing autonomic neuropathy symptoms, include specific interventions indicated by the manifestations (for example, for abnormal sweating or nocturnal diarrhoea).	The MHRA advised that healthcare professionals should test for raised ketones in people with ketoacidosis symptoms who are receiving an SGLT-2 inhibitor, even if their plasma glucose levels are near-normal.	It advises that if the combination is used, people should be observed for signs and symptoms of heart failure, weight gain, and oedema	
meal	0	1.1204	6	Individualise recommendations for carbohydrate and alcohol intake, and meal patterns	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks.	Consider pre-mixed (biphasic) preparations that include short-acting insulin analogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals.	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	
diarrhoea	0	1.1136	2	Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015	In managing autonomic neuropathy symptoms, include specific interventions indicated by the manifestations (for example, for abnormal sweating or nocturnal diarrhoea).	
m2	1	1.1075	5	Stop metformin if the eGFR is below 30 ml minute m2.	Stop metformin if the eGFR is below 30 ml minute m2.	In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute m2:	Prescribe metformin with caution for those at risk of a sudden deterioration in kidney function and those at risk of eGFR falling below 45 ml minute m2.	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	
pioglitazone	1	1.1053	20	pioglitazone or a sulfonylurea.	When prescribing pioglitazone, exercise particular caution if the person is at high risk of the adverse effects of the drug	Pioglitazone is associated with an increased risk of heart failure, bladder cancer and bone fracture	When prescribing pioglitazone, exercise particular caution if the person is at high risk of the adverse effects of the drug	Pioglitazone is associated with an increased risk of heart failure, bladder cancer and bone fracture	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	pioglitazone or a sulfonylurea.	When prescribing pioglitazone, exercise particular caution if the person is at high risk of the adverse effects of the drug	Pioglitazone is associated with an increased risk of heart failure, bladder cancer and bone fracture	When prescribing pioglitazone, exercise particular caution if the person is at high risk of the adverse effects of the drug	Pioglitazone is associated with an increased risk of heart failure, bladder cancer and bone fracture	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea.	In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure	In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Pioglitazone should be discontinued if any deterioration in cardiac status occurs.	
effects	0	1.0962	14	When prescribing pioglitazone, exercise particular caution if the person is at high risk of the adverse effects of the drug	When prescribing pioglitazone, exercise particular caution if the person is at high risk of the adverse effects of the drug	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2014) notes that domperidone is associated with a small increased risk of serious cardiac side effects	Domperidone is now contraindicated in certain groups in whom the risk of cardiac effects is higher; its marketing authorisations have also been restricted to its use in the relief of nausea and vomiting only, at the lowest effective dose and for the shortest possible time (usually not more than 1 week): see the	When prescribing pioglitazone, exercise particular caution if the person is at high risk of the adverse effects of the drug	When prescribing pioglitazone, exercise particular caution if the person is at high risk of the adverse effects of the drug	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2014) notes that domperidone is associated with a small increased risk of serious cardiac side effects	Domperidone is now contraindicated in certain groups in whom the risk of cardiac effects is higher; its marketing authorisations have also been restricted to its use in the relief of nausea and vomiting only, at the lowest effective dose and for the shortest possible time (usually not more than 1 week): see the	Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life.	Check for possible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure.	Encourage them to achieve the target and maintain it unless any resulting adverse effects (including hypoglycaemia), or their efforts to achieve their target, impair their quality of life.	Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes.	If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin.	When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension.	
loss	1	1.0942	8	Remember that lesser degrees of weight loss may still be of benefit, and that larger degrees of weight loss in the longer term will have advantageous metabolic impact.	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).	Remember that lesser degrees of weight loss may still be of benefit, and that larger degrees of weight loss in the longer term will have advantageous metabolic impact.	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).	For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent	Be aware that there are other possible reasons for a low HbA1c level, for example, deteriorating renal function or sudden weight loss.	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment.	
self-monitoring	0	1.0916	7	Self-monitoring of blood glucose	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia.	If adults with type 2 diabetes are self-monitoring their blood glucose levels, carry out a structured assessment at least annually	The assessment should include: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used.	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
antihypertensive	0	1.0912	7	For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used.	Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor	The first-line antihypertensive drug treatment for a person of African or	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant.	Check for possible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure.	When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension.	
inhibitor	1	1.0865	20	For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor.	If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist).	For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor.	If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist).	First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor	Caribbean family origin should be an ACE inhibitor plus either a diuretic or a generic calcium-channel blocker.	Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension.	Recommendations in this section that cover dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) mimetics and sulfonylureas refer to each of these groups of drugs at a class level.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea.	Treatment with sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some adults with type 2 diabetes if metformin is contraindicated or not tolerated (see NICE's guidance on canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes).	In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	Treatment with combinations of medicines including sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in triple therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Consider a phosphodiesterase-5 inhibitor to treat problematic erectile dysfunction in men with type 2 diabetes, initially choosing the drug with the lowest acquisition cost and taking into account any contraindications.	Following discussion, refer men with type 2 diabetes to a service offering other medical, surgical or psychological management of erectile dysfunction if treatment (including a phosphodiesterase-5 inhibitor, as appropriate) has been unsuccessful.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2016) warned that serious, life-threatening, and fatal cases of diabetic ketoacidosis have been reported rarely in people taking an SGLT-2 inhibitor (a substantial proportion of the cases concerned off-label use in people with type 1 diabetes, which is not recommended)	The MHRA advised that healthcare professionals should test for raised ketones in people with ketoacidosis symptoms who are receiving an SGLT-2 inhibitor, even if their plasma glucose levels are near-normal.	
family	1	1.0864	5	Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with	It has specific aims and learning objectives, and supports the person and their family members and carers in developing attitudes, beliefs, knowledge and skills to self-manage diabetes.	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	African or Caribbean family origin, or women for whom there is a possibility of becoming pregnant.	Caribbean family origin should be an ACE inhibitor plus either a diuretic or a generic calcium-channel blocker.	
review	1	1.0771	15	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Reassess the person's needs and circumstances at each review and think about whether to stop any medicines that are not effective.	Last updated May 2017 annual reinforcement and review	It is quality assured, and reviewed by trained, competent, independent assessors who measure it against criteria that ensure consistency.	For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used.	Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia.	Review treatment as necessary.	If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations – ) or a sulfonylurea, and review treatment when blood glucose control has been achieved.	In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute m2:	Review the continued need for other blood glucose lowering therapies .	Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review.	Depending on the findings, follow structured eye screening by: routine review in 1 year or earlier review or referral to an ophthalmologist.	Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment.	Arrange rapid review by an ophthalmologist for new vessel formation.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	
contraindications	0	1.0729	2	When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance	Consider a phosphodiesterase-5 inhibitor to treat problematic erectile dysfunction in men with type 2 diabetes, initially choosing the drug with the lowest acquisition cost and taking into account any contraindications.	
injection	1	1.0673	5	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections.	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections.	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if: the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs.	Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	
mhra	0	1.0614	17	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	At the time of publication (March 2017) evidence did not show an increased risk for dapagliflozin and empagliflozin, but the MHRA advised that the risk may be a class effect.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2014) notes that domperidone is associated with a small increased risk of serious cardiac side effects	MHRA guidance and summaries of product characteristics	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	At the time of publication (March 2017) evidence did not show an increased risk for dapagliflozin and empagliflozin, but the MHRA advised that the risk may be a class effect.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2014) notes that domperidone is associated with a small increased risk of serious cardiac side effects	MHRA guidance and summaries of product characteristics	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2016) warned that serious, life-threatening, and fatal cases of diabetic ketoacidosis have been reported rarely in people taking an SGLT-2 inhibitor (a substantial proportion of the cases concerned off-label use in people with type 1 diabetes, which is not recommended)	The MHRA advised that healthcare professionals should test for raised ketones in people with ketoacidosis symptoms who are receiving an SGLT-2 inhibitor, even if their plasma glucose levels are near-normal.	The MHRA advises that prescribers should take into account the overall safety profile of domperidone, and in particular its cardiac risk and potential interactions with other medicines (such as erythromycin), if there is a clinical need to use it at doses or durations greater than those authorised	
weight	1	1.0607	11	Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight.	Remember that lesser degrees of weight loss may still be of benefit, and that larger degrees of weight loss in the longer term will have advantageous metabolic impact.	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).	Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight.	Remember that lesser degrees of weight loss may still be of benefit, and that larger degrees of weight loss in the longer term will have advantageous metabolic impact.	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).	For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	Be aware that there are other possible reasons for a low HbA1c level, for example, deteriorating renal function or sudden weight loss.	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	It advises that if the combination is used, people should be observed for signs and symptoms of heart failure, weight gain, and oedema	
hba1c	1	1.0544	26	If HbA1c monitoring is invalid because of disturbed erythrocyte turnover or abnormal haemoglobin type, estimate trends in blood glucose control using one	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).	HbA1c is 75 mmol mol  percent or higher), administered either: separately or as a pre-mixed (biphasic) human insulin preparation.	HbA1c reached or who cannot use the device needed to inject NPH insulin but who could administer their own insulin safely and accurately if a switch to one of the long-acting insulin analogues was made or	If HbA1c monitoring is invalid because of disturbed erythrocyte turnover or abnormal haemoglobin type, estimate trends in blood glucose control using one	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).	HbA1c is 75 mmol mol  percent or higher), administered either: separately or as a pre-mixed (biphasic) human insulin preparation.	HbA1c reached or who cannot use the device needed to inject NPH insulin but who could administer their own insulin safely and accurately if a switch to one of the long-acting insulin analogues was made or	HbA1c measurement and targets	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	Use methods to measure HbA1c that have been calibrated according to	Investigate unexplained discrepancies between HbA1c and other glucose measurements	Involve adults with type 2 diabetes in decisions about their individual HbA1c target	Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section )	For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol ( percent)	For adults on a drug associated with hypoglycaemia, support the person to aim for an HbA1c level of 53 mmol mol ( percent).	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	Consider relaxing the target HbA1c level (see recommendations and )	If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it	Be aware that there are other possible reasons for a low HbA1c level, for example, deteriorating renal function or sudden weight loss.	For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy.	In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations – ).	Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	
intensification	1	1.0513	10	However, discuss with any person for whom repaglinide is being considered, that there is no licensed non-metformin-based combination containing repaglinide that can be offered at first intensification.	First intensification of drug treatment	Second intensification of drug treatment	First intensification of drug treatment	In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	Second intensification of drug treatment	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations – ).	However, discuss with any person for whom repaglinide is being considered, that there is no licensed non-metformin-based combination containing repaglinide that can be offered at first intensification.	
recommendation	0	1.0513	12	Last updated May 2017 1 Recommendations	The wording used in the recommendations in this guideline (for example, words such as 'offer' and 'consider') denotes the certainty with which the recommendation is made (the strength of the recommendation)	Individualise recommendations for carbohydrate and alcohol intake, and meal patterns	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	Consider relaxing the target HbA1c level (see recommendations and )	Recommendations in this section that cover dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) mimetics and sulfonylureas refer to each of these groups of drugs at a class level.	If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations – ) or a sulfonylurea, and review treatment when blood glucose control has been achieved.	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations – ).	The recommendations in this guideline also apply to any current and future biosimilar product(s) of insulin glargine that have an appropriate marketing authorisation that allows the use of the biosimilar(s) in the same indication.	
products	1	1.0502	11	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2014) notes that domperidone is associated with a small increased risk of serious cardiac side effects	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2014) notes that domperidone is associated with a small increased risk of serious cardiac side effects	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Encourage high-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids.	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2016) warned that serious, life-threatening, and fatal cases of diabetic ketoacidosis have been reported rarely in people taking an SGLT-2 inhibitor (a substantial proportion of the cases concerned off-label use in people with type 1 diabetes, which is not recommended)	
threshold	0	1.0482	4	In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations – ).	
regulatory	1	1.0395	10	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2014) notes that domperidone is associated with a small increased risk of serious cardiac side effects	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2014) notes that domperidone is associated with a small increased risk of serious cardiac side effects	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2016) warned that serious, life-threatening, and fatal cases of diabetic ketoacidosis have been reported rarely in people taking an SGLT-2 inhibitor (a substantial proportion of the cases concerned off-label use in people with type 1 diabetes, which is not recommended)	
lifestyle	0	1.0394	12	Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight.	Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight.	Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	Offer and reinforce preventive lifestyle advice.	Provide lifestyle advice (diet and exercise) at the same time.	Provide lifestyle advice (see section in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood	Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section )	For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol ( percent)	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if: the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs.	
eye	1	1.0372	15	Last updated May 2017 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Eye disease	Arrange repeat structured eye screening annually. 2009, amended 2016	Perform visual acuity testing as a routine part of eye screening programmes.	Last updated May 2017 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Eye disease	Arrange repeat structured eye screening annually. 2009, amended 2016	Perform visual acuity testing as a routine part of eye screening programmes.	Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage.	Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	On diagnosis, GPs should immediately refer adults with type 2 diabetes to the local eye screening service	Explain the reasons for, and success of, eye screening systems to adults with type 2 diabetes, so that attendance is not reduced by lack of knowledge or fear of outcome.	Depending on the findings, follow structured eye screening by: routine review in 1 year or earlier review or referral to an ophthalmologist.	
opportunity	1	1.0344	2	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review.	
team	0	1.0344	6	Seek advice from a team with specialist expertise in diabetes or clinical biochemistry.	A consultant-led multidisciplinary team may include a wide range of staff based in primary, secondary and community care.	Seek advice from a team with specialist expertise in diabetes or clinical biochemistry.	A consultant-led multidisciplinary team may include a wide range of staff based in primary, secondary and community care.	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team .	
time	0	1.0317	11	Committee criteria and timelines if any of these features are present: referable maculopathy: exudate or retinal thickening within 1 disc diameter of the centre of the fovea	At the time of publication (March 2017) evidence did not show an increased risk for dapagliflozin and empagliflozin, but the MHRA advised that the risk may be a class effect.	Domperidone is now contraindicated in certain groups in whom the risk of cardiac effects is higher; its marketing authorisations have also been restricted to its use in the relief of nausea and vomiting only, at the lowest effective dose and for the shortest possible time (usually not more than 1 week): see the	At the time of publication (December 2015), erythromycin did not have a UK marketing	Committee criteria and timelines if any of these features are present: referable maculopathy: exudate or retinal thickening within 1 disc diameter of the centre of the fovea	At the time of publication (March 2017) evidence did not show an increased risk for dapagliflozin and empagliflozin, but the MHRA advised that the risk may be a class effect.	Domperidone is now contraindicated in certain groups in whom the risk of cardiac effects is higher; its marketing authorisations have also been restricted to its use in the relief of nausea and vomiting only, at the lowest effective dose and for the shortest possible time (usually not more than 1 week): see the	At the time of publication (December 2015), erythromycin did not have a UK marketing	Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with	Ensure the patient-education programme provides the necessary resources to support the educators, and that educators are properly trained and given time to develop and maintain their skills.	Provide lifestyle advice (diet and exercise) at the same time.	
metformin	1	1.0227	19	Stop metformin if the eGFR is below 30 ml minute m2.	Stop metformin if the eGFR is below 30 ml minute m2.	Be aware that, if metformin is contraindicated or not tolerated, repaglinide is both clinically effective and cost effective in adults with type 2 diabetes	However, discuss with any person for whom repaglinide is being considered, that there is no licensed non-metformin-based combination containing repaglinide that can be offered at first intensification.	Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes.	Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes.	If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin.	In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute m2:	Prescribe metformin with caution for those at risk of a sudden deterioration in kidney function and those at risk of eGFR falling below 45 ml minute m2.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea.	Treatment with sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some adults with type 2 diabetes if metformin is contraindicated or not tolerated (see NICE's guidance on canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes).	In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations – ).	When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance	Be aware that, if metformin is contraindicated or not tolerated, repaglinide is both clinically effective and cost effective in adults with type 2 diabetes	However, discuss with any person for whom repaglinide is being considered, that there is no licensed non-metformin-based combination containing repaglinide that can be offered at first intensification.	
section	0	1.0205	5	For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	Provide lifestyle advice (see section in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood	Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section )	Recommendations in this section that cover dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) mimetics and sulfonylureas refer to each of these groups of drugs at a class level.	For guidance on insulin delivery for adults with type 2 diabetes, see the insulin delivery section in the NICE guideline on type 1 diabetes.	
knowledge	1	1.0187	2	It has specific aims and learning objectives, and supports the person and their family members and carers in developing attitudes, beliefs, knowledge and skills to self-manage diabetes.	Explain the reasons for, and success of, eye screening systems to adults with type 2 diabetes, so that attendance is not reduced by lack of knowledge or fear of outcome.	
measure	0	1.0187	8	It is quality assured, and reviewed by trained, competent, independent assessors who measure it against criteria that ensure consistency.	Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease	Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage.	HbA1c measurement and targets	Measurement	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	Use methods to measure HbA1c that have been calibrated according to	Investigate unexplained discrepancies between HbA1c and other glucose measurements	
service	0	1.0187	4	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	If gastroparesis is suspected, consider referral to specialist services if: the differential diagnosis is in doubt or persistent or severe vomiting occurs.	Following discussion, refer men with type 2 diabetes to a service offering other medical, surgical or psychological management of erectile dysfunction if treatment (including a phosphodiesterase-5 inhibitor, as appropriate) has been unsuccessful.	On diagnosis, GPs should immediately refer adults with type 2 diabetes to the local eye screening service	
deterioration	0	1.0153	6	For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor.	Last updated May 2017 circinate or group of exudates within the macula (the macula is defined here as a circle centred on the fovea, with a diameter the distance between the temporal border of the optic disc and the fovea) any microaneurysm or haemorrhage within 1 disc diameter of the centre of the fovea, only if associated with deterioration of best visual acuity to 6 12 or worse. referable pre-proliferative retinopathy (if cotton wool spots are present, look carefully for the following features, but cotton wool spots themselves do not define pre-proliferative retinopathy): any venous beading any venous reduplication any intraretinal microvascular abnormalities multiple deep, round or blot haemorrhages. any large, sudden unexplained drop in visual acuity 2009, amended 2015	For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor.	Last updated May 2017 circinate or group of exudates within the macula (the macula is defined here as a circle centred on the fovea, with a diameter the distance between the temporal border of the optic disc and the fovea) any microaneurysm or haemorrhage within 1 disc diameter of the centre of the fovea, only if associated with deterioration of best visual acuity to 6 12 or worse. referable pre-proliferative retinopathy (if cotton wool spots are present, look carefully for the following features, but cotton wool spots themselves do not define pre-proliferative retinopathy): any venous beading any venous reduplication any intraretinal microvascular abnormalities multiple deep, round or blot haemorrhages. any large, sudden unexplained drop in visual acuity 2009, amended 2015	Prescribe metformin with caution for those at risk of a sudden deterioration in kidney function and those at risk of eGFR falling below 45 ml minute m2.	Pioglitazone should be discontinued if any deterioration in cardiac status occurs.	
glp-1	1	1.0139	5	Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	Recommendations in this section that cover dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) mimetics and sulfonylureas refer to each of these groups of drugs at a class level.	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team .	
groups	1	1.0139	4	Domperidone is now contraindicated in certain groups in whom the risk of cardiac effects is higher; its marketing authorisations have also been restricted to its use in the relief of nausea and vomiting only, at the lowest effective dose and for the shortest possible time (usually not more than 1 week): see the	Domperidone is now contraindicated in certain groups in whom the risk of cardiac effects is higher; its marketing authorisations have also been restricted to its use in the relief of nausea and vomiting only, at the lowest effective dose and for the shortest possible time (usually not more than 1 week): see the	Recommendations in this section that cover dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) mimetics and sulfonylureas refer to each of these groups of drugs at a class level.	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	
peptide-1	1	1.0139	2	Recommendations in this section that cover dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) mimetics and sulfonylureas refer to each of these groups of drugs at a class level.	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	
support	0	1.0138	15	It has a structured curriculum that is theory-driven, evidence-based and resource-effective, has supporting materials, and is written down.	For more information about supporting adherence, see the NICE guideline on medicines adherence.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	It has a structured curriculum that is theory-driven, evidence-based and resource-effective, has supporting materials, and is written down.	For more information about supporting adherence, see the NICE guideline on medicines adherence.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	It has specific aims and learning objectives, and supports the person and their family members and carers in developing attitudes, beliefs, knowledge and skills to self-manage diabetes.	Ensure the patient-education programme provides the necessary resources to support the educators, and that educators are properly trained and given time to develop and maintain their skills.	Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section )	For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol ( percent)	For adults on a drug associated with hypoglycaemia, support the person to aim for an HbA1c level of 53 mmol mol ( percent).	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team .	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options.	
advise	0	1.0	8	At the time of publication (March 2017) evidence did not show an increased risk for dapagliflozin and empagliflozin, but the MHRA advised that the risk may be a class effect.	At the time of publication (March 2017) evidence did not show an increased risk for dapagliflozin and empagliflozin, but the MHRA advised that the risk may be a class effect.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	The MHRA advised that healthcare professionals should test for raised ketones in people with ketoacidosis symptoms who are receiving an SGLT-2 inhibitor, even if their plasma glucose levels are near-normal.	It advises that if the combination is used, people should be observed for signs and symptoms of heart failure, weight gain, and oedema	The MHRA advises that prescribers should take into account the overall safety profile of domperidone, and in particular its cardiac risk and potential interactions with other medicines (such as erythromycin), if there is a clinical need to use it at doses or durations greater than those authorised	
aim	1	1.0	5	It has specific aims and learning objectives, and supports the person and their family members and carers in developing attitudes, beliefs, knowledge and skills to self-manage diabetes.	Reducing the risk of hypoglycaemia should be a particular aim for a person using insulin or an insulin secretagogue.	For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol ( percent)	For adults on a drug associated with hypoglycaemia, support the person to aim for an HbA1c level of 53 mmol mol ( percent).	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	
aims	1	1.0	1	It has specific aims and learning objectives, and supports the person and their family members and carers in developing attitudes, beliefs, knowledge and skills to self-manage diabetes.	
alcohol	1	1.0	1	Individualise recommendations for carbohydrate and alcohol intake, and meal patterns	
angiotensin	1	1.0	6	For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor.	If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist).	For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor.	If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist).	First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor	Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension.	
antagonist	1	1.0	5	For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor.	If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist).	For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor.	If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist).	Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension.	
antiplatelet	0	1.0	3	Antiplatelet therapy	Antiplatelet therapy	Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease.	
aspirin	1	1.0	1	Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease.	
assess	0	1.0	5	Reassess the person's needs and circumstances at each review and think about whether to stop any medicines that are not effective.	It is quality assured, and reviewed by trained, competent, independent assessors who measure it against criteria that ensure consistency.	If adults with type 2 diabetes are self-monitoring their blood glucose levels, carry out a structured assessment at least annually	The assessment should include: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used.	Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options.	
assessors	0	1.0	1	It is quality assured, and reviewed by trained, competent, independent assessors who measure it against criteria that ensure consistency.	
attitudes	0	1.0	1	It has specific aims and learning objectives, and supports the person and their family members and carers in developing attitudes, beliefs, knowledge and skills to self-manage diabetes.	
authorisation	0	1.0	3	Domperidone is now contraindicated in certain groups in whom the risk of cardiac effects is higher; its marketing authorisations have also been restricted to its use in the relief of nausea and vomiting only, at the lowest effective dose and for the shortest possible time (usually not more than 1 week): see the	Domperidone is now contraindicated in certain groups in whom the risk of cardiac effects is higher; its marketing authorisations have also been restricted to its use in the relief of nausea and vomiting only, at the lowest effective dose and for the shortest possible time (usually not more than 1 week): see the	The recommendations in this guideline also apply to any current and future biosimilar product(s) of insulin glargine that have an appropriate marketing authorisation that allows the use of the biosimilar(s) in the same indication.	
biosimilar(s)	0	1.0	1	The recommendations in this guideline also apply to any current and future biosimilar product(s) of insulin glargine that have an appropriate marketing authorisation that allows the use of the biosimilar(s) in the same indication.	
bladder	0	1.0	7	Pioglitazone is associated with an increased risk of heart failure, bladder cancer and bone fracture	Last updated May 2017 hepatic impairment diabetic ketoacidosis current, or a history of, bladder cancer uninvestigated macroscopic haematuria.	Pioglitazone is associated with an increased risk of heart failure, bladder cancer and bone fracture	Pioglitazone is associated with an increased risk of heart failure, bladder cancer and bone fracture	Last updated May 2017 hepatic impairment diabetic ketoacidosis current, or a history of, bladder cancer uninvestigated macroscopic haematuria.	Pioglitazone is associated with an increased risk of heart failure, bladder cancer and bone fracture	Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems.	
bladder-emptying	0	1.0	1	Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems.	
body	0	1.0	3	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).	For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent	
changes	1	1.0	3	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	Make changes only if there is poor control or if current drug treatment is not appropriate because of microvascular complications or metabolic problems.	
clopidogrel	1	1.0	1	Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease.	
competencies	0	1.0	1	Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition.	
complications	0	1.0	3	Managing complications	Managing complications	Make changes only if there is poor control or if current drug treatment is not appropriate because of microvascular complications or metabolic problems.	
components	0	1.0	1	Ensure that any structured education programme for adults with type 2 diabetes includes the following components:	
content	1	1.0	3	It is delivered by trained educators who have an understanding of educational theory appropriate to the age and needs of the person, and who are trained and competent to deliver the principles and content of the programme.	It is delivered by trained educators who have an understanding of educational theory appropriate to the age and needs of the person, and who are trained and competent to deliver the principles and content of the programme.	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks.	
corticosteroids	0	1.0	1	Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia.	
criteria	1	1.0	3	Committee criteria and timelines if any of these features are present: referable maculopathy: exudate or retinal thickening within 1 disc diameter of the centre of the fovea	Committee criteria and timelines if any of these features are present: referable maculopathy: exudate or retinal thickening within 1 disc diameter of the centre of the fovea	It is quality assured, and reviewed by trained, competent, independent assessors who measure it against criteria that ensure consistency.	
culture	0	1.0	1	Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life.	
detachment	0	1.0	1	Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment.	
disabilities	0	1.0	1	Take into account any disabilities, including visual impairment, when planning and delivering care for adults with type 2 diabetes.	
discussions	1	1.0	1	Discussions should include precautions for driving.	
diuretic	1	1.0	7	If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic)	Add the other drug (that is, the calcium-channel blocker or diuretic) if the target is not reached with dual therapy 2009, amended 2015	If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist).	If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic)	Add the other drug (that is, the calcium-channel blocker or diuretic) if the target is not reached with dual therapy 2009, amended 2015	If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist).	Caribbean family origin should be an ACE inhibitor plus either a diuretic or a generic calcium-channel blocker.	
doubt	0	1.0	1	If gastroparesis is suspected, consider referral to specialist services if: the differential diagnosis is in doubt or persistent or severe vomiting occurs.	
driving	0	1.0	2	Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	Discussions should include precautions for driving.	
emergency	0	1.0	1	Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment.	
energy	1	1.0	1	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	
enzyme	1	1.0	1	First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor	
exercise	0	1.0	5	When prescribing pioglitazone, exercise particular caution if the person is at high risk of the adverse effects of the drug	When prescribing pioglitazone, exercise particular caution if the person is at high risk of the adverse effects of the drug	When prescribing pioglitazone, exercise particular caution if the person is at high risk of the adverse effects of the drug	When prescribing pioglitazone, exercise particular caution if the person is at high risk of the adverse effects of the drug	Provide lifestyle advice (diet and exercise) at the same time.	
expertise	1	1.0	3	Seek advice from a team with specialist expertise in diabetes or clinical biochemistry.	Seek advice from a team with specialist expertise in diabetes or clinical biochemistry.	Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition.	
findings	0	1.0	1	Depending on the findings, follow structured eye screening by: routine review in 1 year or earlier review or referral to an ophthalmologist.	
form	1	1.0	34	For more information about supporting adherence, see the NICE guideline on medicines adherence.	Stop metformin if the eGFR is below 30 ml minute m2.	Perform screening as soon as possible and no later than 3 months from referral	Use mydriasis with tropicamide when photographing the retina, after prior informed agreement following discussion of the advantages and disadvantages.	Perform visual acuity testing as a routine part of eye screening programmes.	See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.	For more information about supporting adherence, see the NICE guideline on medicines adherence.	Stop metformin if the eGFR is below 30 ml minute m2.	Perform screening as soon as possible and no later than 3 months from referral	Use mydriasis with tropicamide when photographing the retina, after prior informed agreement following discussion of the advantages and disadvantages.	Perform visual acuity testing as a routine part of eye screening programmes.	See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.	Be aware that, if metformin is contraindicated or not tolerated, repaglinide is both clinically effective and cost effective in adults with type 2 diabetes	However, discuss with any person for whom repaglinide is being considered, that there is no licensed non-metformin-based combination containing repaglinide that can be offered at first intensification.	Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life.	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant.	For more information, see the NICE guideline on diabetes in pregnancy.	Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes.	Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes.	If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin.	In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute m2:	Prescribe metformin with caution for those at risk of a sudden deterioration in kidney function and those at risk of eGFR falling below 45 ml minute m2.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea.	Treatment with sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some adults with type 2 diabetes if metformin is contraindicated or not tolerated (see NICE's guidance on canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes).	In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations – ).	When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance	Arrange rapid review by an ophthalmologist for new vessel formation.	Be aware that, if metformin is contraindicated or not tolerated, repaglinide is both clinically effective and cost effective in adults with type 2 diabetes	However, discuss with any person for whom repaglinide is being considered, that there is no licensed non-metformin-based combination containing repaglinide that can be offered at first intensification.	Informed consent should be obtained and documented	
formation	0	1.0	6	For more information about supporting adherence, see the NICE guideline on medicines adherence.	See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.	For more information about supporting adherence, see the NICE guideline on medicines adherence.	See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.	For more information, see the NICE guideline on diabetes in pregnancy.	Arrange rapid review by an ophthalmologist for new vessel formation.	
group	1	1.0	9	Offer group education programmes as the preferred option	Last updated May 2017 circinate or group of exudates within the macula (the macula is defined here as a circle centred on the fovea, with a diameter the distance between the temporal border of the optic disc and the fovea) any microaneurysm or haemorrhage within 1 disc diameter of the centre of the fovea, only if associated with deterioration of best visual acuity to 6 12 or worse. referable pre-proliferative retinopathy (if cotton wool spots are present, look carefully for the following features, but cotton wool spots themselves do not define pre-proliferative retinopathy): any venous beading any venous reduplication any intraretinal microvascular abnormalities multiple deep, round or blot haemorrhages. any large, sudden unexplained drop in visual acuity 2009, amended 2015	Domperidone is now contraindicated in certain groups in whom the risk of cardiac effects is higher; its marketing authorisations have also been restricted to its use in the relief of nausea and vomiting only, at the lowest effective dose and for the shortest possible time (usually not more than 1 week): see the	Offer group education programmes as the preferred option	Last updated May 2017 circinate or group of exudates within the macula (the macula is defined here as a circle centred on the fovea, with a diameter the distance between the temporal border of the optic disc and the fovea) any microaneurysm or haemorrhage within 1 disc diameter of the centre of the fovea, only if associated with deterioration of best visual acuity to 6 12 or worse. referable pre-proliferative retinopathy (if cotton wool spots are present, look carefully for the following features, but cotton wool spots themselves do not define pre-proliferative retinopathy): any venous beading any venous reduplication any intraretinal microvascular abnormalities multiple deep, round or blot haemorrhages. any large, sudden unexplained drop in visual acuity 2009, amended 2015	Domperidone is now contraindicated in certain groups in whom the risk of cardiac effects is higher; its marketing authorisations have also been restricted to its use in the relief of nausea and vomiting only, at the lowest effective dose and for the shortest possible time (usually not more than 1 week): see the	Provide an alternative of equal standard for a person unable or unwilling to participate in group education.	Recommendations in this section that cover dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) mimetics and sulfonylureas refer to each of these groups of drugs at a class level.	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	
haemorrhage	0	1.0	3	Last updated May 2017 circinate or group of exudates within the macula (the macula is defined here as a circle centred on the fovea, with a diameter the distance between the temporal border of the optic disc and the fovea) any microaneurysm or haemorrhage within 1 disc diameter of the centre of the fovea, only if associated with deterioration of best visual acuity to 6 12 or worse. referable pre-proliferative retinopathy (if cotton wool spots are present, look carefully for the following features, but cotton wool spots themselves do not define pre-proliferative retinopathy): any venous beading any venous reduplication any intraretinal microvascular abnormalities multiple deep, round or blot haemorrhages. any large, sudden unexplained drop in visual acuity 2009, amended 2015	Last updated May 2017 circinate or group of exudates within the macula (the macula is defined here as a circle centred on the fovea, with a diameter the distance between the temporal border of the optic disc and the fovea) any microaneurysm or haemorrhage within 1 disc diameter of the centre of the fovea, only if associated with deterioration of best visual acuity to 6 12 or worse. referable pre-proliferative retinopathy (if cotton wool spots are present, look carefully for the following features, but cotton wool spots themselves do not define pre-proliferative retinopathy): any venous beading any venous reduplication any intraretinal microvascular abnormalities multiple deep, round or blot haemorrhages. any large, sudden unexplained drop in visual acuity 2009, amended 2015	Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment.	
hospital	0	1.0	1	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks.	
hyperglycaemia	0	1.0	1	Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia	
ii-receptor	0	1.0	5	For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor.	If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist).	For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor.	If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist).	Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension.	
illness	0	1.0	1	Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia	
impairment	1	1.0	3	Last updated May 2017 hepatic impairment diabetic ketoacidosis current, or a history of, bladder cancer uninvestigated macroscopic haematuria.	Last updated May 2017 hepatic impairment diabetic ketoacidosis current, or a history of, bladder cancer uninvestigated macroscopic haematuria.	Take into account any disabilities, including visual impairment, when planning and delivering care for adults with type 2 diabetes.	
indication	0	1.0	4	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance	Consider a phosphodiesterase-5 inhibitor to treat problematic erectile dysfunction in men with type 2 diabetes, initially choosing the drug with the lowest acquisition cost and taking into account any contraindications.	The recommendations in this guideline also apply to any current and future biosimilar product(s) of insulin glargine that have an appropriate marketing authorisation that allows the use of the biosimilar(s) in the same indication.	
individualise	1	1.0	5	Individualised care	Individualised care	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition.	Individualise recommendations for carbohydrate and alcohol intake, and meal patterns	
inpatients	0	1.0	1	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks.	
investigate	1	1.0	4	Last updated May 2017 hepatic impairment diabetic ketoacidosis current, or a history of, bladder cancer uninvestigated macroscopic haematuria.	Last updated May 2017 hepatic impairment diabetic ketoacidosis current, or a history of, bladder cancer uninvestigated macroscopic haematuria.	Investigate unexplained discrepancies between HbA1c and other glucose measurements	Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems.	
iridis	0	1.0	1	Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment.	
manifestations	1	1.0	1	In managing autonomic neuropathy symptoms, include specific interventions indicated by the manifestations (for example, for abnormal sweating or nocturnal diarrhoea).	
manner	0	1.0	1	Be aware that the drugs in dual therapy should be introduced in a stepwise manner, checking for tolerability and effectiveness of each drug.	
marketing	0	1.0	5	Domperidone is now contraindicated in certain groups in whom the risk of cardiac effects is higher; its marketing authorisations have also been restricted to its use in the relief of nausea and vomiting only, at the lowest effective dose and for the shortest possible time (usually not more than 1 week): see the	At the time of publication (December 2015), erythromycin did not have a UK marketing	Domperidone is now contraindicated in certain groups in whom the risk of cardiac effects is higher; its marketing authorisations have also been restricted to its use in the relief of nausea and vomiting only, at the lowest effective dose and for the shortest possible time (usually not more than 1 week): see the	At the time of publication (December 2015), erythromycin did not have a UK marketing	The recommendations in this guideline also apply to any current and future biosimilar product(s) of insulin glargine that have an appropriate marketing authorisation that allows the use of the biosimilar(s) in the same indication.	
medications	1	1.0	3	Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used.	
mimetics	0	1.0	1	Recommendations in this section that cover dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) mimetics and sulfonylureas refer to each of these groups of drugs at a class level.	
modified-release	0	1.0	1	If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin.	
nutrition	0	1.0	1	Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition.	
objectives	0	1.0	1	It has specific aims and learning objectives, and supports the person and their family members and carers in developing attitudes, beliefs, knowledge and skills to self-manage diabetes.	
oedema	0	1.0	1	It advises that if the combination is used, people should be observed for signs and symptoms of heart failure, weight gain, and oedema	
once-daily	0	1.0	1	First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor	
pain	0	1.0	3	Painful diabetic neuropathy	Painful diabetic neuropathy	For guidance on managing painful diabetic peripheral neuropathy in adults with type 2 diabetes, see the NICE guideline on neuropathic pain in adults.	
patterns	0	1.0	1	Individualise recommendations for carbohydrate and alcohol intake, and meal patterns	
phase	0	1.0	1	Rescue therapy at any phase of treatment	
plan	1	1.0	7	Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight.	Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight.	Take into account any disabilities, including visual impairment, when planning and delivering care for adults with type 2 diabetes.	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks.	For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy.	Last updated May 2017 the person is pregnant, or is planning to become pregnant	
planning	1	1.0	4	Take into account any disabilities, including visual impairment, when planning and delivering care for adults with type 2 diabetes.	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks.	For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy.	Last updated May 2017 the person is pregnant, or is planning to become pregnant	
precautions	0	1.0	1	Discussions should include precautions for driving.	
product(s)	0	1.0	1	The recommendations in this guideline also apply to any current and future biosimilar product(s) of insulin glargine that have an appropriate marketing authorisation that allows the use of the biosimilar(s) in the same indication.	
reassess	0	1.0	1	Reassess the person's needs and circumstances at each review and think about whether to stop any medicines that are not effective.	
rescue	0	1.0	1	Rescue therapy at any phase of treatment	
rubeosis	0	1.0	1	Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment.	
secretagogue	1	1.0	1	Reducing the risk of hypoglycaemia should be a particular aim for a person using insulin or an insulin secretagogue.	
self-manage	0	1.0	1	It has specific aims and learning objectives, and supports the person and their family members and carers in developing attitudes, beliefs, knowledge and skills to self-manage diabetes.	
snacks	0	1.0	1	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks.	
standard	0	1.0	9	International Federation of Clinical Chemistry (IFCC) standardisation.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	International Federation of Clinical Chemistry (IFCC) standardisation.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	Provide an alternative of equal standard for a person unable or unwilling to participate in group education.	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes.	Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes.	If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin.	
status	1	1.0	1	Pioglitazone should be discontinued if any deterioration in cardiac status occurs.	
substitution	0	1.0	1	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	
sucrose-containing	0	1.0	1	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	
sulfonylureas	0	1.0	1	Recommendations in this section that cover dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) mimetics and sulfonylureas refer to each of these groups of drugs at a class level.	
targets	0	1.0	4	Targets	Targets	HbA1c measurement and targets	For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy.	
trial	1	1.0	1	If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin.	
vessel	0	1.0	1	Arrange rapid review by an ophthalmologist for new vessel formation.	
vision	1	1.0	2	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	Arrange emergency review by an ophthalmologist for: sudden loss of vision rubeosis iridis pre-retinal or vitreous haemorrhage retinal detachment.	
weeks	1	1.0	1	Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes.	
willingness	0	1.0	1	Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life.	
woman	0	1.0	1	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant.	
year	1	1.0	1	Depending on the findings, follow structured eye screening by: routine review in 1 year or earlier review or referral to an ophthalmologist.	
ensure	0	0.9989	8	Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area.	Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Ensure that any structured education programme for adults with type 2 diabetes includes the following components:	It is quality assured, and reviewed by trained, competent, independent assessors who measure it against criteria that ensure consistency.	Ensure the patient-education programme provides the necessary resources to support the educators, and that educators are properly trained and given time to develop and maintain their skills.	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	
encourage	1	0.9933	3	Encourage high-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids.	Encourage them to achieve the target and maintain it unless any resulting adverse effects (including hypoglycaemia), or their efforts to achieve their target, impair their quality of life.	If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it	
account	1	0.9925	8	Last updated May 2017 take into account its safety profile, in particular its cardiac risk and potential interactions with other medicines.	Last updated May 2017 take into account its safety profile, in particular its cardiac risk and potential interactions with other medicines.	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	Take into account any disabilities, including visual impairment, when planning and delivering care for adults with type 2 diabetes.	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015	Consider a phosphodiesterase-5 inhibitor to treat problematic erectile dysfunction in men with type 2 diabetes, initially choosing the drug with the lowest acquisition cost and taking into account any contraindications.	The MHRA advises that prescribers should take into account the overall safety profile of domperidone, and in particular its cardiac risk and potential interactions with other medicines (such as erythromycin), if there is a clinical need to use it at doses or durations greater than those authorised	
agency	1	0.9895	11	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2014) notes that domperidone is associated with a small increased risk of serious cardiac side effects	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2014) notes that domperidone is associated with a small increased risk of serious cardiac side effects	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2016) warned that serious, life-threatening, and fatal cases of diabetic ketoacidosis have been reported rarely in people taking an SGLT-2 inhibitor (a substantial proportion of the cases concerned off-label use in people with type 1 diabetes, which is not recommended)	
acquisition	0	0.9885	2	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Consider a phosphodiesterase-5 inhibitor to treat problematic erectile dysfunction in men with type 2 diabetes, initially choosing the drug with the lowest acquisition cost and taking into account any contraindications.	
advice	0	0.9869	18	Dietary advice and bariatric surgery	Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight.	Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Seek advice from a team with specialist expertise in diabetes or clinical biochemistry.	Dietary advice and bariatric surgery	Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight.	Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Seek advice from a team with specialist expertise in diabetes or clinical biochemistry.	Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition.	Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life.	Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	Offer and reinforce preventive lifestyle advice.	Provide lifestyle advice (diet and exercise) at the same time.	Provide lifestyle advice (see section in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood	Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section )	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team .	
skills	0	0.9855	3	It has specific aims and learning objectives, and supports the person and their family members and carers in developing attitudes, beliefs, knowledge and skills to self-manage diabetes.	Ensure the patient-education programme provides the necessary resources to support the educators, and that educators are properly trained and given time to develop and maintain their skills.	The assessment should include: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used.	
programme	1	0.983	14	It is delivered by trained educators who have an understanding of educational theory appropriate to the age and needs of the person, and who are trained and competent to deliver the principles and content of the programme.	Offer group education programmes as the preferred option	Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area.	Use a quality-assured digital retinal photography programme using appropriately trained staff.	Perform visual acuity testing as a routine part of eye screening programmes.	It is delivered by trained educators who have an understanding of educational theory appropriate to the age and needs of the person, and who are trained and competent to deliver the principles and content of the programme.	Offer group education programmes as the preferred option	Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area.	Use a quality-assured digital retinal photography programme using appropriately trained staff.	Perform visual acuity testing as a routine part of eye screening programmes.	Ensure that any structured education programme for adults with type 2 diabetes includes the following components:	Ensure the patient-education programme provides the necessary resources to support the educators, and that educators are properly trained and given time to develop and maintain their skills.	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
risks	0	0.9735	4	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	Check for possible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure.	For adults with type 2 diabetes, discuss the benefits and risks of drug treatment, and the options available	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	
combination	0	0.9711	14	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	However, discuss with any person for whom repaglinide is being considered, that there is no licensed non-metformin-based combination containing repaglinide that can be offered at first intensification.	Treatment with 2 non-insulin blood glucose lowering therapies in combination (dual therapy)	Treatment with either 3 non-insulin blood glucose lowering therapies in combination (triple therapy) or any treatment combination containing insulin	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Treatment with combinations of medicines including sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team .	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in triple therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if: the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs.	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	However, discuss with any person for whom repaglinide is being considered, that there is no licensed non-metformin-based combination containing repaglinide that can be offered at first intensification.	It advises that if the combination is used, people should be observed for signs and symptoms of heart failure, weight gain, and oedema	
acids	1	0.9689	1	Encourage high-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids.	
dairy	0	0.9689	1	Encourage high-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids.	
eating	0	0.9689	7	Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes	Treatment with sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some adults with type 2 diabetes if metformin is contraindicated or not tolerated (see NICE's guidance on canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes).	Treatment with combinations of medicines including sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in triple therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance.	In managing autonomic neuropathy symptoms, include specific interventions indicated by the manifestations (for example, for abnormal sweating or nocturnal diarrhoea).	
emphasise	0	0.9689	1	Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes	
fish	0	0.9689	1	Encourage high-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids.	
fruit	1	0.9689	1	Encourage high-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids.	
high-fibre	0	0.9689	1	Encourage high-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids.	
population	1	0.9689	1	Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes	
pulses	0	0.9689	1	Encourage high-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids.	
sources	1	0.9689	2	Ensure the patient-education programme provides the necessary resources to support the educators, and that educators are properly trained and given time to develop and maintain their skills.	Encourage high-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids.	
trans	0	0.9689	3	Encourage high-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids.	Treatment with sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some adults with type 2 diabetes if metformin is contraindicated or not tolerated (see NICE's guidance on canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes).	Treatment with combinations of medicines including sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	
vegetables	0	0.9689	1	Encourage high-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids.	
wholegrains	0	0.9689	1	Encourage high-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids.	
care	1	0.9688	34	Individualised care	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections.	Last updated May 2017 circinate or group of exudates within the macula (the macula is defined here as a circle centred on the fovea, with a diameter the distance between the temporal border of the optic disc and the fovea) any microaneurysm or haemorrhage within 1 disc diameter of the centre of the fovea, only if associated with deterioration of best visual acuity to 6 12 or worse. referable pre-proliferative retinopathy (if cotton wool spots are present, look carefully for the following features, but cotton wool spots themselves do not define pre-proliferative retinopathy): any venous beading any venous reduplication any intraretinal microvascular abnormalities multiple deep, round or blot haemorrhages. any large, sudden unexplained drop in visual acuity 2009, amended 2015	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	A consultant-led multidisciplinary team may include a wide range of staff based in primary, secondary and community care.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2014) notes that domperidone is associated with a small increased risk of serious cardiac side effects	Individualised care	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections.	Last updated May 2017 circinate or group of exudates within the macula (the macula is defined here as a circle centred on the fovea, with a diameter the distance between the temporal border of the optic disc and the fovea) any microaneurysm or haemorrhage within 1 disc diameter of the centre of the fovea, only if associated with deterioration of best visual acuity to 6 12 or worse. referable pre-proliferative retinopathy (if cotton wool spots are present, look carefully for the following features, but cotton wool spots themselves do not define pre-proliferative retinopathy): any venous beading any venous reduplication any intraretinal microvascular abnormalities multiple deep, round or blot haemorrhages. any large, sudden unexplained drop in visual acuity 2009, amended 2015	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	A consultant-led multidisciplinary team may include a wide range of staff based in primary, secondary and community care.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2014) notes that domperidone is associated with a small increased risk of serious cardiac side effects	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	Take into account any disabilities, including visual impairment, when planning and delivering care for adults with type 2 diabetes.	Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with	Explain to people and their carers that structured education is an integral part of diabetes care.	It has specific aims and learning objectives, and supports the person and their family members and carers in developing attitudes, beliefs, knowledge and skills to self-manage diabetes.	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition.	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks.	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team .	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if: the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs.	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2016) warned that serious, life-threatening, and fatal cases of diabetic ketoacidosis have been reported rarely in people taking an SGLT-2 inhibitor (a substantial proportion of the cases concerned off-label use in people with type 1 diabetes, which is not recommended)	The MHRA advised that healthcare professionals should test for raised ketones in people with ketoacidosis symptoms who are receiving an SGLT-2 inhibitor, even if their plasma glucose levels are near-normal.	
needs	1	0.9684	12	It is evidence-based, and suits the needs of the person.	It is delivered by trained educators who have an understanding of educational theory appropriate to the age and needs of the person, and who are trained and competent to deliver the principles and content of the programme.	Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area.	It is evidence-based, and suits the needs of the person.	It is delivered by trained educators who have an understanding of educational theory appropriate to the age and needs of the person, and who are trained and competent to deliver the principles and content of the programme.	Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area.	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	Reassess the person's needs and circumstances at each review and think about whether to stop any medicines that are not effective.	Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life.	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if: the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs.	
vomiting	0	0.964	6	Domperidone is now contraindicated in certain groups in whom the risk of cardiac effects is higher; its marketing authorisations have also been restricted to its use in the relief of nausea and vomiting only, at the lowest effective dose and for the shortest possible time (usually not more than 1 week): see the	Domperidone is now contraindicated in certain groups in whom the risk of cardiac effects is higher; its marketing authorisations have also been restricted to its use in the relief of nausea and vomiting only, at the lowest effective dose and for the shortest possible time (usually not more than 1 week): see the	Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015	For adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that: there is not strong evidence that any available antiemetic therapy is effective some people have had benefit with domperidone , erythromycin or metoclopramide . the strongest evidence for effectiveness is for domperidone , but prescribers must	For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance.	If gastroparesis is suspected, consider referral to specialist services if: the differential diagnosis is in doubt or persistent or severe vomiting occurs.	
diagnosis	0	0.9608	4	Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with	Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015	If gastroparesis is suspected, consider referral to specialist services if: the differential diagnosis is in doubt or persistent or severe vomiting occurs.	On diagnosis, GPs should immediately refer adults with type 2 diabetes to the local eye screening service	
healthcare	1	0.9467	18	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2014) notes that domperidone is associated with a small increased risk of serious cardiac side effects	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2014) notes that domperidone is associated with a small increased risk of serious cardiac side effects	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition.	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if: the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2016) warned that serious, life-threatening, and fatal cases of diabetic ketoacidosis have been reported rarely in people taking an SGLT-2 inhibitor (a substantial proportion of the cases concerned off-label use in people with type 1 diabetes, which is not recommended)	The MHRA advised that healthcare professionals should test for raised ketones in people with ketoacidosis symptoms who are receiving an SGLT-2 inhibitor, even if their plasma glucose levels are near-normal.	
target	0	0.9451	20	If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic)	Add the other drug (that is, the calcium-channel blocker or diuretic) if the target is not reached with dual therapy 2009, amended 2015	If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist).	Monitor the blood pressure of a person who has attained and consistently remained at his or her blood pressure target every 4–6 months	Targets	If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic)	Add the other drug (that is, the calcium-channel blocker or diuretic) if the target is not reached with dual therapy 2009, amended 2015	If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist).	Monitor the blood pressure of a person who has attained and consistently remained at his or her blood pressure target every 4–6 months	Targets	For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent	HbA1c measurement and targets	Involve adults with type 2 diabetes in decisions about their individual HbA1c target	Encourage them to achieve the target and maintain it unless any resulting adverse effects (including hypoglycaemia), or their efforts to achieve their target, impair their quality of life.	Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section )	Consider relaxing the target HbA1c level (see recommendations and )	If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it	For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy.	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	
gain	0	0.9441	3	It is quality assured, and reviewed by trained, competent, independent assessors who measure it against criteria that ensure consistency.	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	It advises that if the combination is used, people should be observed for signs and symptoms of heart failure, weight gain, and oedema	
control	1	0.9403	18	If HbA1c monitoring is invalid because of disturbed erythrocyte turnover or abnormal haemoglobin type, estimate trends in blood glucose control using one	Last updated May 2017 of the following: quality-controlled plasma glucose profiles total glycated haemoglobin estimation (if abnormal haemoglobins) fructosamine estimation.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	If HbA1c monitoring is invalid because of disturbed erythrocyte turnover or abnormal haemoglobin type, estimate trends in blood glucose control using one	Last updated May 2017 of the following: quality-controlled plasma glucose profiles total glycated haemoglobin estimation (if abnormal haemoglobins) fructosamine estimation.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	Encourage high-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids.	For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used.	Make changes only if there is poor control or if current drug treatment is not appropriate because of microvascular complications or metabolic problems.	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations – ) or a sulfonylurea, and review treatment when blood glucose control has been achieved.	In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations – ).	Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015	
information	0	0.9372	5	For more information about supporting adherence, see the NICE guideline on medicines adherence.	See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.	For more information about supporting adherence, see the NICE guideline on medicines adherence.	See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.	For more information, see the NICE guideline on diabetes in pregnancy.	
medication	1	0.9372	4	Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used.	Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	
damage	0	0.933	7	Last updated May 2017 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Last updated May 2017 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage.	Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015	
class	0	0.9259	4	At the time of publication (March 2017) evidence did not show an increased risk for dapagliflozin and empagliflozin, but the MHRA advised that the risk may be a class effect.	At the time of publication (March 2017) evidence did not show an increased risk for dapagliflozin and empagliflozin, but the MHRA advised that the risk may be a class effect.	Recommendations in this section that cover dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) mimetics and sulfonylureas refer to each of these groups of drugs at a class level.	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	
options	0	0.9259	2	For adults with type 2 diabetes, discuss the benefits and risks of drug treatment, and the options available	Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options.	
tolerability	0	0.9259	2	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Be aware that the drugs in dual therapy should be introduced in a stepwise manner, checking for tolerability and effectiveness of each drug.	
offer	0	0.9229	19	Offer group education programmes as the preferred option	Offer NPH insulin injected once or twice daily according to need.	Offer group education programmes as the preferred option	Offer NPH insulin injected once or twice daily according to need.	However, discuss with any person for whom repaglinide is being considered, that there is no licensed non-metformin-based combination containing repaglinide that can be offered at first intensification.	The wording used in the recommendations in this guideline (for example, words such as 'offer' and 'consider') denotes the certainty with which the recommendation is made (the strength of the recommendation)	Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with	Offer and reinforce preventive lifestyle advice.	Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease.	Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section )	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes.	In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure	In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team .	When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance	Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review.	Following discussion, refer men with type 2 diabetes to a service offering other medical, surgical or psychological management of erectile dysfunction if treatment (including a phosphodiesterase-5 inhibitor, as appropriate) has been unsuccessful.	However, discuss with any person for whom repaglinide is being considered, that there is no licensed non-metformin-based combination containing repaglinide that can be offered at first intensification.	
part	1	0.92	16	When prescribing pioglitazone, exercise particular caution if the person is at high risk of the adverse effects of the drug	Last updated May 2017 take into account its safety profile, in particular its cardiac risk and potential interactions with other medicines.	Perform visual acuity testing as a routine part of eye screening programmes.	When prescribing pioglitazone, exercise particular caution if the person is at high risk of the adverse effects of the drug	When prescribing pioglitazone, exercise particular caution if the person is at high risk of the adverse effects of the drug	Last updated May 2017 take into account its safety profile, in particular its cardiac risk and potential interactions with other medicines.	Perform visual acuity testing as a routine part of eye screening programmes.	When prescribing pioglitazone, exercise particular caution if the person is at high risk of the adverse effects of the drug	Explain to people and their carers that structured education is an integral part of diabetes care.	Provide an alternative of equal standard for a person unable or unwilling to participate in group education.	Reducing the risk of hypoglycaemia should be a particular aim for a person using insulin or an insulin secretagogue.	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	Consider starting both NPH and short-acting insulin (particularly if the person's	Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015	Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review.	The MHRA advises that prescribers should take into account the overall safety profile of domperidone, and in particular its cardiac risk and potential interactions with other medicines (such as erythromycin), if there is a clinical need to use it at doses or durations greater than those authorised	
level	1	0.919	18	In several cases, blood glucose levels were only moderately elevated	In several cases, blood glucose levels were only moderately elevated	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol ( percent)	For adults on a drug associated with hypoglycaemia, support the person to aim for an HbA1c level of 53 mmol mol ( percent).	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	Consider relaxing the target HbA1c level (see recommendations and )	If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it	Be aware that there are other possible reasons for a low HbA1c level, for example, deteriorating renal function or sudden weight loss.	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia.	If adults with type 2 diabetes are self-monitoring their blood glucose levels, carry out a structured assessment at least annually	Recommendations in this section that cover dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) mimetics and sulfonylureas refer to each of these groups of drugs at a class level.	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	Consider pre-mixed (biphasic) preparations that include short-acting insulin analogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals.	Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	The MHRA advised that healthcare professionals should test for raised ketones in people with ketoacidosis symptoms who are receiving an SGLT-2 inhibitor, even if their plasma glucose levels are near-normal.	
evidence	0	0.9181	12	The following guidance is based on the best available evidence	The full guideline gives details of the methods and the evidence used to develop the guidance.	It is evidence-based, and suits the needs of the person.	It has a structured curriculum that is theory-driven, evidence-based and resource-effective, has supporting materials, and is written down.	At the time of publication (March 2017) evidence did not show an increased risk for dapagliflozin and empagliflozin, but the MHRA advised that the risk may be a class effect.	The following guidance is based on the best available evidence	The full guideline gives details of the methods and the evidence used to develop the guidance.	It is evidence-based, and suits the needs of the person.	It has a structured curriculum that is theory-driven, evidence-based and resource-effective, has supporting materials, and is written down.	At the time of publication (March 2017) evidence did not show an increased risk for dapagliflozin and empagliflozin, but the MHRA advised that the risk may be a class effect.	Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	For adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that: there is not strong evidence that any available antiemetic therapy is effective some people have had benefit with domperidone , erythromycin or metoclopramide . the strongest evidence for effectiveness is for domperidone , but prescribers must	
reasons	0	0.9092	2	Be aware that there are other possible reasons for a low HbA1c level, for example, deteriorating renal function or sudden weight loss.	Explain the reasons for, and success of, eye screening systems to adults with type 2 diabetes, so that attendance is not reduced by lack of knowledge or fear of outcome.	
therapies	0	0.9081	4	Treatment with 2 non-insulin blood glucose lowering therapies in combination (dual therapy)	Treatment with either 3 non-insulin blood glucose lowering therapies in combination (triple therapy) or any treatment combination containing insulin	Treatment with sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some adults with type 2 diabetes if metformin is contraindicated or not tolerated (see NICE's guidance on canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes).	Review the continued need for other blood glucose lowering therapies .	
drug	1	0.9077	39	When prescribing pioglitazone, exercise particular caution if the person is at high risk of the adverse effects of the drug	Add the other drug (that is, the calcium-channel blocker or diuretic) if the target is not reached with dual therapy 2009, amended 2015	When prescribing pioglitazone, exercise particular caution if the person is at high risk of the adverse effects of the drug	When prescribing pioglitazone, exercise particular caution if the person is at high risk of the adverse effects of the drug	Add the other drug (that is, the calcium-channel blocker or diuretic) if the target is not reached with dual therapy 2009, amended 2015	When prescribing pioglitazone, exercise particular caution if the person is at high risk of the adverse effects of the drug	Initial drug treatment	First intensification of drug treatment	Second intensification of drug treatment	For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used.	Make changes only if there is poor control or if current drug treatment is not appropriate because of microvascular complications or metabolic problems.	Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor	The first-line antihypertensive drug treatment for a person of African or	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant.	Check for possible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure.	Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section )	For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol ( percent)	For adults on a drug associated with hypoglycaemia, support the person to aim for an HbA1c level of 53 mmol mol ( percent).	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	Drug treatment	Recommendations in this section that cover dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) mimetics and sulfonylureas refer to each of these groups of drugs at a class level.	For adults with type 2 diabetes, discuss the benefits and risks of drug treatment, and the options available	Base the choice of drug treatment(s) on: the effectiveness of the drug treatment(s) in terms of metabolic response	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Initial drug treatment	Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea.	First intensification of drug treatment	In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	Second intensification of drug treatment	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations – ).	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if: the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs.	When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension.	Consider a phosphodiesterase-5 inhibitor to treat problematic erectile dysfunction in men with type 2 diabetes, initially choosing the drug with the lowest acquisition cost and taking into account any contraindications.	Be aware that the drugs in dual therapy should be introduced in a stepwise manner, checking for tolerability and effectiveness of each drug.	
function	1	0.9055	8	Erectile dysfunction	Erectile dysfunction	Be aware that there are other possible reasons for a low HbA1c level, for example, deteriorating renal function or sudden weight loss.	Prescribe metformin with caution for those at risk of a sudden deterioration in kidney function and those at risk of eGFR falling below 45 ml minute m2.	Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review.	Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options.	Consider a phosphodiesterase-5 inhibitor to treat problematic erectile dysfunction in men with type 2 diabetes, initially choosing the drug with the lowest acquisition cost and taking into account any contraindications.	Following discussion, refer men with type 2 diabetes to a service offering other medical, surgical or psychological management of erectile dysfunction if treatment (including a phosphodiesterase-5 inhibitor, as appropriate) has been unsuccessful.	
people	1	0.9007	18	Discourage the use of foods marketed specifically for people with diabetes.	Exceptions to this are people of	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	Discourage the use of foods marketed specifically for people with diabetes.	Exceptions to this are people of	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	Explain to people and their carers that structured education is an integral part of diabetes care.	For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	Treatment with combinations of medicines including sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in triple therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	For adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that: there is not strong evidence that any available antiemetic therapy is effective some people have had benefit with domperidone , erythromycin or metoclopramide . the strongest evidence for effectiveness is for domperidone , but prescribers must	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2016) warned that serious, life-threatening, and fatal cases of diabetic ketoacidosis have been reported rarely in people taking an SGLT-2 inhibitor (a substantial proportion of the cases concerned off-label use in people with type 1 diabetes, which is not recommended)	The MHRA advised that healthcare professionals should test for raised ketones in people with ketoacidosis symptoms who are receiving an SGLT-2 inhibitor, even if their plasma glucose levels are near-normal.	It advises that if the combination is used, people should be observed for signs and symptoms of heart failure, weight gain, and oedema	
kidney	1	0.8889	11	Last updated May 2017 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Diabetic kidney disease	Last updated May 2017 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Diabetic kidney disease	Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage.	Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Prescribe metformin with caution for those at risk of a sudden deterioration in kidney function and those at risk of eGFR falling below 45 ml minute m2.	For guidance on managing kidney disease in adults with type 2 diabetes, see the	NICE guideline on chronic kidney disease in adults.	
nph	1	0.8863	9	Offer NPH insulin injected once or twice daily according to need.	HbA1c reached or who cannot use the device needed to inject NPH insulin but who could administer their own insulin safely and accurately if a switch to one of the long-acting insulin analogues was made or	Offer NPH insulin injected once or twice daily according to need.	HbA1c reached or who cannot use the device needed to inject NPH insulin but who could administer their own insulin safely and accurately if a switch to one of the long-acting insulin analogues was made or	Consider starting both NPH and short-acting insulin (particularly if the person's	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if: the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs.	Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	
alternative	0	0.8785	3	Provide an alternative of equal standard for a person unable or unwilling to participate in group education.	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if: the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs.	Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015	
hypoglycaemia	0	0.8751	13	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	Reducing the risk of hypoglycaemia should be a particular aim for a person using insulin or an insulin secretagogue.	Encourage them to achieve the target and maintain it unless any resulting adverse effects (including hypoglycaemia), or their efforts to achieve their target, impair their quality of life.	For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol ( percent)	For adults on a drug associated with hypoglycaemia, support the person to aim for an HbA1c level of 53 mmol mol ( percent).	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it	Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia.	Consider pre-mixed (biphasic) preparations that include short-acting insulin analogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals.	Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015	
recommendations	0	0.8751	11	Last updated May 2017 1 Recommendations	The wording used in the recommendations in this guideline (for example, words such as 'offer' and 'consider') denotes the certainty with which the recommendation is made (the strength of the recommendation)	Individualise recommendations for carbohydrate and alcohol intake, and meal patterns	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	Consider relaxing the target HbA1c level (see recommendations and )	Recommendations in this section that cover dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) mimetics and sulfonylureas refer to each of these groups of drugs at a class level.	If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations – ) or a sulfonylurea, and review treatment when blood glucose control has been achieved.	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations – ).	The recommendations in this guideline also apply to any current and future biosimilar product(s) of insulin glargine that have an appropriate marketing authorisation that allows the use of the biosimilar(s) in the same indication.	
treatments	0	0.8737	2	Insulin-based treatments	When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension.	
dapagliflozin	0	0.8719	6	At the time of publication (March 2017) evidence did not show an increased risk for dapagliflozin and empagliflozin, but the MHRA advised that the risk may be a class effect.	At the time of publication (March 2017) evidence did not show an increased risk for dapagliflozin and empagliflozin, but the MHRA advised that the risk may be a class effect.	Treatment with sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some adults with type 2 diabetes if metformin is contraindicated or not tolerated (see NICE's guidance on canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes).	Treatment with combinations of medicines including sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in triple therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	
drugs	1	0.8678	7	Recommendations in this section that cover dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) mimetics and sulfonylureas refer to each of these groups of drugs at a class level.	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations – ).	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if: the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs.	When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension.	Be aware that the drugs in dual therapy should be introduced in a stepwise manner, checking for tolerability and effectiveness of each drug.	
therapy	1	0.8669	31	If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic)	Add the other drug (that is, the calcium-channel blocker or diuretic) if the target is not reached with dual therapy 2009, amended 2015	If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist).	Antiplatelet therapy	Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic)	Add the other drug (that is, the calcium-channel blocker or diuretic) if the target is not reached with dual therapy 2009, amended 2015	If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist).	Antiplatelet therapy	Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	Treatment with a single non-insulin blood glucose lowering therapy (monotherapy)	Treatment with 2 non-insulin blood glucose lowering therapies in combination (dual therapy)	Treatment with either 3 non-insulin blood glucose lowering therapies in combination (triple therapy) or any treatment combination containing insulin	Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease.	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	Rescue therapy at any phase of treatment	Algorithm for blood glucose lowering therapy in adults with type 2 diabetes	In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	Treatment with combinations of medicines including sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations – ).	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in triple therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance	Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	For adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that: there is not strong evidence that any available antiemetic therapy is effective some people have had benefit with domperidone , erythromycin or metoclopramide . the strongest evidence for effectiveness is for domperidone , but prescribers must	Be aware that the drugs in dual therapy should be introduced in a stepwise manner, checking for tolerability and effectiveness of each drug.	
guideline	0	0.8578	20	The full guideline gives details of the methods and the evidence used to develop the guidance.	See about this guideline for details.	Terms used in this guideline	For more information about supporting adherence, see the NICE guideline on medicines adherence.	The full guideline gives details of the methods and the evidence used to develop the guidance.	See about this guideline for details.	Terms used in this guideline	For more information about supporting adherence, see the NICE guideline on medicines adherence.	The wording used in the recommendations in this guideline (for example, words such as 'offer' and 'consider') denotes the certainty with which the recommendation is made (the strength of the recommendation)	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	Provide lifestyle advice (see section in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy.	For more information, see the NICE guideline on diabetes in pregnancy.	For guidance on insulin delivery for adults with type 2 diabetes, see the insulin delivery section in the NICE guideline on type 1 diabetes.	For guidance on managing painful diabetic peripheral neuropathy in adults with type 2 diabetes, see the NICE guideline on neuropathic pain in adults.	For guidance on preventing and managing foot problems in adults with type 2 diabetes, see the NICE guideline on diabetic foot problems.	NICE guideline on chronic kidney disease in adults.	The recommendations in this guideline also apply to any current and future biosimilar product(s) of insulin glargine that have an appropriate marketing authorisation that allows the use of the biosimilar(s) in the same indication.	
machinery	0	0.8541	2	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	
gut	1	0.8445	1	Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015	
hypotension	1	0.8445	1	When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension.	
likelihood	0	0.8445	1	When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension.	
night	0	0.8445	1	Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015	
patient-education	0	0.8401	4	Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area.	Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area.	Ensure the patient-education programme provides the necessary resources to support the educators, and that educators are properly trained and given time to develop and maintain their skills.	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	
effectiveness	0	0.8393	3	Base the choice of drug treatment(s) on: the effectiveness of the drug treatment(s) in terms of metabolic response	For adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that: there is not strong evidence that any available antiemetic therapy is effective some people have had benefit with domperidone , erythromycin or metoclopramide . the strongest evidence for effectiveness is for domperidone , but prescribers must	Be aware that the drugs in dual therapy should be introduced in a stepwise manner, checking for tolerability and effectiveness of each drug.	
infarction	1	0.8363	1	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	
prevention	0	0.8363	1	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	
explain	0	0.8356	9	Last updated May 2017 circinate or group of exudates within the macula (the macula is defined here as a circle centred on the fovea, with a diameter the distance between the temporal border of the optic disc and the fovea) any microaneurysm or haemorrhage within 1 disc diameter of the centre of the fovea, only if associated with deterioration of best visual acuity to 6 12 or worse. referable pre-proliferative retinopathy (if cotton wool spots are present, look carefully for the following features, but cotton wool spots themselves do not define pre-proliferative retinopathy): any venous beading any venous reduplication any intraretinal microvascular abnormalities multiple deep, round or blot haemorrhages. any large, sudden unexplained drop in visual acuity 2009, amended 2015	Last updated May 2017 circinate or group of exudates within the macula (the macula is defined here as a circle centred on the fovea, with a diameter the distance between the temporal border of the optic disc and the fovea) any microaneurysm or haemorrhage within 1 disc diameter of the centre of the fovea, only if associated with deterioration of best visual acuity to 6 12 or worse. referable pre-proliferative retinopathy (if cotton wool spots are present, look carefully for the following features, but cotton wool spots themselves do not define pre-proliferative retinopathy): any venous beading any venous reduplication any intraretinal microvascular abnormalities multiple deep, round or blot haemorrhages. any large, sudden unexplained drop in visual acuity 2009, amended 2015	Explain to people and their carers that structured education is an integral part of diabetes care.	Investigate unexplained discrepancies between HbA1c and other glucose measurements	Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015	For adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that: there is not strong evidence that any available antiemetic therapy is effective some people have had benefit with domperidone , erythromycin or metoclopramide . the strongest evidence for effectiveness is for domperidone , but prescribers must	Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015	Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems.	Explain the reasons for, and success of, eye screening systems to adults with type 2 diabetes, so that attendance is not reduced by lack of knowledge or fear of outcome.	
medicines	0	0.8321	21	For more information about supporting adherence, see the NICE guideline on medicines adherence.	Last updated May 2017 take into account its safety profile, in particular its cardiac risk and potential interactions with other medicines.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2014) notes that domperidone is associated with a small increased risk of serious cardiac side effects	See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.	For more information about supporting adherence, see the NICE guideline on medicines adherence.	Last updated May 2017 take into account its safety profile, in particular its cardiac risk and potential interactions with other medicines.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2014) notes that domperidone is associated with a small increased risk of serious cardiac side effects	See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Reassess the person's needs and circumstances at each review and think about whether to stop any medicines that are not effective.	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Treatment with combinations of medicines including sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in triple therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2016) warned that serious, life-threatening, and fatal cases of diabetic ketoacidosis have been reported rarely in people taking an SGLT-2 inhibitor (a substantial proportion of the cases concerned off-label use in people with type 1 diabetes, which is not recommended)	The MHRA advises that prescribers should take into account the overall safety profile of domperidone, and in particular its cardiac risk and potential interactions with other medicines (such as erythromycin), if there is a clinical need to use it at doses or durations greater than those authorised	
glargine	1	0.8273	5	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if: the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs.	Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	The recommendations in this guideline also apply to any current and future biosimilar product(s) of insulin glargine that have an appropriate marketing authorisation that allows the use of the biosimilar(s) in the same indication.	
sglt-2	1	0.8242	6	Treatment with sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some adults with type 2 diabetes if metformin is contraindicated or not tolerated (see NICE's guidance on canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes).	Treatment with combinations of medicines including sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in triple therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2016) warned that serious, life-threatening, and fatal cases of diabetic ketoacidosis have been reported rarely in people taking an SGLT-2 inhibitor (a substantial proportion of the cases concerned off-label use in people with type 1 diabetes, which is not recommended)	The MHRA advised that healthcare professionals should test for raised ketones in people with ketoacidosis symptoms who are receiving an SGLT-2 inhibitor, even if their plasma glucose levels are near-normal.	
inhibitors	1	0.813	5	Recommendations in this section that cover dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) mimetics and sulfonylureas refer to each of these groups of drugs at a class level.	Treatment with sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some adults with type 2 diabetes if metformin is contraindicated or not tolerated (see NICE's guidance on canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes).	Treatment with combinations of medicines including sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in triple therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	
driver	0	0.809	1	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	
dvla	0	0.809	3	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	
fitness	0	0.809	3	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	
glance	0	0.809	3	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	
guide	0	0.809	23	The full guideline gives details of the methods and the evidence used to develop the guidance.	See about this guideline for details.	Terms used in this guideline	For more information about supporting adherence, see the NICE guideline on medicines adherence.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	The full guideline gives details of the methods and the evidence used to develop the guidance.	See about this guideline for details.	Terms used in this guideline	For more information about supporting adherence, see the NICE guideline on medicines adherence.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	The wording used in the recommendations in this guideline (for example, words such as 'offer' and 'consider') denotes the certainty with which the recommendation is made (the strength of the recommendation)	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	Provide lifestyle advice (see section in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy.	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	For more information, see the NICE guideline on diabetes in pregnancy.	For guidance on insulin delivery for adults with type 2 diabetes, see the insulin delivery section in the NICE guideline on type 1 diabetes.	For guidance on managing painful diabetic peripheral neuropathy in adults with type 2 diabetes, see the NICE guideline on neuropathic pain in adults.	For guidance on preventing and managing foot problems in adults with type 2 diabetes, see the NICE guideline on diabetic foot problems.	NICE guideline on chronic kidney disease in adults.	The recommendations in this guideline also apply to any current and future biosimilar product(s) of insulin glargine that have an appropriate marketing authorisation that allows the use of the biosimilar(s) in the same indication.	
licensing	1	0.809	1	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	
standards	0	0.809	3	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	
vehicle	0	0.809	1	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	
diagnoses	0	0.8002	1	Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015	
erythromycin	1	0.8002	4	At the time of publication (December 2015), erythromycin did not have a UK marketing	At the time of publication (December 2015), erythromycin did not have a UK marketing	For adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that: there is not strong evidence that any available antiemetic therapy is effective some people have had benefit with domperidone , erythromycin or metoclopramide . the strongest evidence for effectiveness is for domperidone , but prescribers must	The MHRA advises that prescribers should take into account the overall safety profile of domperidone, and in particular its cardiac risk and potential interactions with other medicines (such as erythromycin), if there is a clinical need to use it at doses or durations greater than those authorised	
interventions	0	0.8001	4	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	Provide lifestyle advice (see section in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood	In managing autonomic neuropathy symptoms, include specific interventions indicated by the manifestations (for example, for abnormal sweating or nocturnal diarrhoea).	
guidelines	0	0.7904	2	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	
reinforcement	0	0.7891	1	Last updated May 2017 annual reinforcement and review	
metoclopramide	1	0.7884	2	For adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that: there is not strong evidence that any available antiemetic therapy is effective some people have had benefit with domperidone , erythromycin or metoclopramide . the strongest evidence for effectiveness is for domperidone , but prescribers must	For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance.	
episodes	0	0.7865	2	Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if: the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs.	
person	0	0.7778	44	When prescribing pioglitazone, exercise particular caution if the person is at high risk of the adverse effects of the drug	It is evidence-based, and suits the needs of the person.	It is delivered by trained educators who have an understanding of educational theory appropriate to the age and needs of the person, and who are trained and competent to deliver the principles and content of the programme.	Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight.	For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor.	If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic)	If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist).	Monitor the blood pressure of a person who has attained and consistently remained at his or her blood pressure target every 4–6 months	Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	When prescribing pioglitazone, exercise particular caution if the person is at high risk of the adverse effects of the drug	When prescribing pioglitazone, exercise particular caution if the person is at high risk of the adverse effects of the drug	It is evidence-based, and suits the needs of the person.	It is delivered by trained educators who have an understanding of educational theory appropriate to the age and needs of the person, and who are trained and competent to deliver the principles and content of the programme.	Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight.	For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor.	If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic)	If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist).	Monitor the blood pressure of a person who has attained and consistently remained at his or her blood pressure target every 4–6 months	Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	When prescribing pioglitazone, exercise particular caution if the person is at high risk of the adverse effects of the drug	However, discuss with any person for whom repaglinide is being considered, that there is no licensed non-metformin-based combination containing repaglinide that can be offered at first intensification.	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	Reassess the person's needs and circumstances at each review and think about whether to stop any medicines that are not effective.	It has specific aims and learning objectives, and supports the person and their family members and carers in developing attitudes, beliefs, knowledge and skills to self-manage diabetes.	Provide an alternative of equal standard for a person unable or unwilling to participate in group education.	Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life.	Reducing the risk of hypoglycaemia should be a particular aim for a person using insulin or an insulin secretagogue.	Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	The first-line antihypertensive drug treatment for a person of African or	For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol ( percent)	For adults on a drug associated with hypoglycaemia, support the person to aim for an HbA1c level of 53 mmol mol ( percent).	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	Last updated May 2017 the person is pregnant, or is planning to become pregnant	The assessment should include: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used.	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations – ).	Consider starting both NPH and short-acting insulin (particularly if the person's	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if: the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs.	Consider pre-mixed (biphasic) preparations that include short-acting insulin analogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals.	However, discuss with any person for whom repaglinide is being considered, that there is no licensed non-metformin-based combination containing repaglinide that can be offered at first intensification.	
cotransporter	1	0.7764	2	Treatment with sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some adults with type 2 diabetes if metformin is contraindicated or not tolerated (see NICE's guidance on canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes).	Treatment with combinations of medicines including sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	
resources	1	0.7714	1	Ensure the patient-education programme provides the necessary resources to support the educators, and that educators are properly trained and given time to develop and maintain their skills.	
blood	1	0.7683	39	Blood pressure management	Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic)	If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist).	Monitor the blood pressure of a person who has attained and consistently remained at his or her blood pressure target every 4–6 months	Blood glucose management	If HbA1c monitoring is invalid because of disturbed erythrocyte turnover or abnormal haemoglobin type, estimate trends in blood glucose control using one	In several cases, blood glucose levels were only moderately elevated	Blood pressure management	Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic)	If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist).	Monitor the blood pressure of a person who has attained and consistently remained at his or her blood pressure target every 4–6 months	Blood glucose management	If HbA1c monitoring is invalid because of disturbed erythrocyte turnover or abnormal haemoglobin type, estimate trends in blood glucose control using one	In several cases, blood glucose levels were only moderately elevated	Treatment with a single non-insulin blood glucose lowering therapy (monotherapy)	Treatment with 2 non-insulin blood glucose lowering therapies in combination (dual therapy)	Treatment with either 3 non-insulin blood glucose lowering therapies in combination (triple therapy) or any treatment combination containing insulin	Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease	For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used.	Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage.	Provide lifestyle advice (see section in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood	Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Check for possible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure.	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	Self-monitoring of blood glucose	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia.	If adults with type 2 diabetes are self-monitoring their blood glucose levels, carry out a structured assessment at least annually	The assessment should include: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used.	If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations – ) or a sulfonylurea, and review treatment when blood glucose control has been achieved.	Algorithm for blood glucose lowering therapy in adults with type 2 diabetes	Review the continued need for other blood glucose lowering therapies .	Consider pre-mixed (biphasic) preparations that include short-acting insulin analogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals.	Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015	
adherence	0	0.7557	3	For more information about supporting adherence, see the NICE guideline on medicines adherence.	For more information about supporting adherence, see the NICE guideline on medicines adherence.	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	
rise	1	0.7557	3	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	Consider pre-mixed (biphasic) preparations that include short-acting insulin analogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals.	The MHRA advises that prescribers should take into account the overall safety profile of domperidone, and in particular its cardiac risk and potential interactions with other medicines (such as erythromycin), if there is a clinical need to use it at doses or durations greater than those authorised	
injections	1	0.7415	4	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections.	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections.	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if: the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs.	
history	0	0.7407	3	Last updated May 2017 hepatic impairment diabetic ketoacidosis current, or a history of, bladder cancer uninvestigated macroscopic haematuria.	Last updated May 2017 hepatic impairment diabetic ketoacidosis current, or a history of, bladder cancer uninvestigated macroscopic haematuria.	In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure	
monotherapies	0	0.7407	1	Treatment with sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some adults with type 2 diabetes if metformin is contraindicated or not tolerated (see NICE's guidance on canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes).	
circumstances	0	0.74	4	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	Reassess the person's needs and circumstances at each review and think about whether to stop any medicines that are not effective.	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance.	
life	0	0.7368	20	Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight.	Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Last updated May 2017 circinate or group of exudates within the macula (the macula is defined here as a circle centred on the fovea, with a diameter the distance between the temporal border of the optic disc and the fovea) any microaneurysm or haemorrhage within 1 disc diameter of the centre of the fovea, only if associated with deterioration of best visual acuity to 6 12 or worse. referable pre-proliferative retinopathy (if cotton wool spots are present, look carefully for the following features, but cotton wool spots themselves do not define pre-proliferative retinopathy): any venous beading any venous reduplication any intraretinal microvascular abnormalities multiple deep, round or blot haemorrhages. any large, sudden unexplained drop in visual acuity 2009, amended 2015	Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight.	Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Last updated May 2017 circinate or group of exudates within the macula (the macula is defined here as a circle centred on the fovea, with a diameter the distance between the temporal border of the optic disc and the fovea) any microaneurysm or haemorrhage within 1 disc diameter of the centre of the fovea, only if associated with deterioration of best visual acuity to 6 12 or worse. referable pre-proliferative retinopathy (if cotton wool spots are present, look carefully for the following features, but cotton wool spots themselves do not define pre-proliferative retinopathy): any venous beading any venous reduplication any intraretinal microvascular abnormalities multiple deep, round or blot haemorrhages. any large, sudden unexplained drop in visual acuity 2009, amended 2015	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life.	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	Offer and reinforce preventive lifestyle advice.	Provide lifestyle advice (diet and exercise) at the same time.	Provide lifestyle advice (see section in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood	Encourage them to achieve the target and maintain it unless any resulting adverse effects (including hypoglycaemia), or their efforts to achieve their target, impair their quality of life.	Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section )	For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol ( percent)	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	The assessment should include: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used.	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if: the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2016) warned that serious, life-threatening, and fatal cases of diabetic ketoacidosis have been reported rarely in people taking an SGLT-2 inhibitor (a substantial proportion of the cases concerned off-label use in people with type 1 diabetes, which is not recommended)	
levels	0	0.7305	11	In several cases, blood glucose levels were only moderately elevated	In several cases, blood glucose levels were only moderately elevated	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia.	If adults with type 2 diabetes are self-monitoring their blood glucose levels, carry out a structured assessment at least annually	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	Consider pre-mixed (biphasic) preparations that include short-acting insulin analogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals.	The MHRA advised that healthcare professionals should test for raised ketones in people with ketoacidosis symptoms who are receiving an SGLT-2 inhibitor, even if their plasma glucose levels are near-normal.	
meals	0	0.7246	4	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks.	Consider pre-mixed (biphasic) preparations that include short-acting insulin analogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals.	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	
design	0	0.7218	1	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	
pathway	1	0.7218	1	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	
provision	0	0.7218	1	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	
rest	1	0.7218	4	Domperidone is now contraindicated in certain groups in whom the risk of cardiac effects is higher; its marketing authorisations have also been restricted to its use in the relief of nausea and vomiting only, at the lowest effective dose and for the shortest possible time (usually not more than 1 week): see the	Domperidone is now contraindicated in certain groups in whom the risk of cardiac effects is higher; its marketing authorisations have also been restricted to its use in the relief of nausea and vomiting only, at the lowest effective dose and for the shortest possible time (usually not more than 1 week): see the	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if: the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs.	
canagliflozin	1	0.7187	6	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	Treatment with sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some adults with type 2 diabetes if metformin is contraindicated or not tolerated (see NICE's guidance on canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes).	Treatment with combinations of medicines including sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in triple therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	
empagliflozin	0	0.7187	6	At the time of publication (March 2017) evidence did not show an increased risk for dapagliflozin and empagliflozin, but the MHRA advised that the risk may be a class effect.	At the time of publication (March 2017) evidence did not show an increased risk for dapagliflozin and empagliflozin, but the MHRA advised that the risk may be a class effect.	Treatment with sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some adults with type 2 diabetes if metformin is contraindicated or not tolerated (see NICE's guidance on canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes).	Treatment with combinations of medicines including sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in triple therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	
obesity	1	0.7157	3	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	
measurements	0	0.7126	2	Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage.	Investigate unexplained discrepancies between HbA1c and other glucose measurements	
decisions	0	0.7032	1	Involve adults with type 2 diabetes in decisions about their individual HbA1c target	
discrepancies	0	0.7032	1	Investigate unexplained discrepancies between HbA1c and other glucose measurements	
efforts	0	0.7032	1	Encourage them to achieve the target and maintain it unless any resulting adverse effects (including hypoglycaemia), or their efforts to achieve their target, impair their quality of life.	
involve	0	0.7032	1	Involve adults with type 2 diabetes in decisions about their individual HbA1c target	
methods	0	0.7032	3	The full guideline gives details of the methods and the evidence used to develop the guidance.	The full guideline gives details of the methods and the evidence used to develop the guidance.	Use methods to measure HbA1c that have been calibrated according to	
attendance	0	0.6952	1	Explain the reasons for, and success of, eye screening systems to adults with type 2 diabetes, so that attendance is not reduced by lack of knowledge or fear of outcome.	
fear	0	0.6952	1	Explain the reasons for, and success of, eye screening systems to adults with type 2 diabetes, so that attendance is not reduced by lack of knowledge or fear of outcome.	
gps	1	0.6952	1	On diagnosis, GPs should immediately refer adults with type 2 diabetes to the local eye screening service	
lack	0	0.6952	2	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	Explain the reasons for, and success of, eye screening systems to adults with type 2 diabetes, so that attendance is not reduced by lack of knowledge or fear of outcome.	
outcome	1	0.6952	3	The outcomes are audited regularly.	The outcomes are audited regularly.	Explain the reasons for, and success of, eye screening systems to adults with type 2 diabetes, so that attendance is not reduced by lack of knowledge or fear of outcome.	
success	0	0.6952	2	Following discussion, refer men with type 2 diabetes to a service offering other medical, surgical or psychological management of erectile dysfunction if treatment (including a phosphodiesterase-5 inhibitor, as appropriate) has been unsuccessful.	Explain the reasons for, and success of, eye screening systems to adults with type 2 diabetes, so that attendance is not reduced by lack of knowledge or fear of outcome.	
systems	1	0.6952	1	Explain the reasons for, and success of, eye screening systems to adults with type 2 diabetes, so that attendance is not reduced by lack of knowledge or fear of outcome.	
treatment	1	0.6939	45	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Initial drug treatment	Treatment with a single non-insulin blood glucose lowering therapy (monotherapy)	First intensification of drug treatment	Treatment with 2 non-insulin blood glucose lowering therapies in combination (dual therapy)	Second intensification of drug treatment	Treatment with either 3 non-insulin blood glucose lowering therapies in combination (triple therapy) or any treatment combination containing insulin	For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used.	Make changes only if there is poor control or if current drug treatment is not appropriate because of microvascular complications or metabolic problems.	Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor	The first-line antihypertensive drug treatment for a person of African or	A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant.	Check for possible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure.	Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section )	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia.	Review treatment as necessary.	Drug treatment	For adults with type 2 diabetes, discuss the benefits and risks of drug treatment, and the options available	Base the choice of drug treatment(s) on: the effectiveness of the drug treatment(s) in terms of metabolic response	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Rescue therapy at any phase of treatment	If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations – ) or a sulfonylurea, and review treatment when blood glucose control has been achieved.	Initial drug treatment	Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea.	Treatment with sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some adults with type 2 diabetes if metformin is contraindicated or not tolerated (see NICE's guidance on canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes).	First intensification of drug treatment	In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	Treatment with combinations of medicines including sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Second intensification of drug treatment	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations – ).	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in triple therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Insulin-based treatments	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance.	When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension.	Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options.	Following discussion, refer men with type 2 diabetes to a service offering other medical, surgical or psychological management of erectile dysfunction if treatment (including a phosphodiesterase-5 inhibitor, as appropriate) has been unsuccessful.	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	
action	0	0.6923	4	Last updated May 2017 take into account its safety profile, in particular its cardiac risk and potential interactions with other medicines.	Last updated May 2017 take into account its safety profile, in particular its cardiac risk and potential interactions with other medicines.	The assessment should include: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used.	The MHRA advises that prescribers should take into account the overall safety profile of domperidone, and in particular its cardiac risk and potential interactions with other medicines (such as erythromycin), if there is a clinical need to use it at doses or durations greater than those authorised	
equipment	0	0.6923	1	The assessment should include: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used.	
impact	1	0.6923	3	Remember that lesser degrees of weight loss may still be of benefit, and that larger degrees of weight loss in the longer term will have advantageous metabolic impact.	Remember that lesser degrees of weight loss may still be of benefit, and that larger degrees of weight loss in the longer term will have advantageous metabolic impact.	The assessment should include: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used.	
results	0	0.6923	1	The assessment should include: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used.	
testing	1	0.6923	3	Perform visual acuity testing as a routine part of eye screening programmes.	Perform visual acuity testing as a routine part of eye screening programmes.	The assessment should include: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used.	
may	1	0.6901	52	Last updated May 2017	Remember that lesser degrees of weight loss may still be of benefit, and that larger degrees of weight loss in the longer term will have advantageous metabolic impact.	Last updated May 2017	Last updated May 2017 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Last updated May 2017	Last updated May 2017 of the following: quality-controlled plasma glucose profiles total glycated haemoglobin estimation (if abnormal haemoglobins) fructosamine estimation.	Last updated May 2017	Last updated May 2017 hepatic impairment diabetic ketoacidosis current, or a history of, bladder cancer uninvestigated macroscopic haematuria.	Last updated May 2017	Last updated May 2017	Last updated May 2017	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections.	Last updated May 2017 take into account its safety profile, in particular its cardiac risk and potential interactions with other medicines.	Last updated May 2017	Last updated May 2017	Last updated May 2017 circinate or group of exudates within the macula (the macula is defined here as a circle centred on the fovea, with a diameter the distance between the temporal border of the optic disc and the fovea) any microaneurysm or haemorrhage within 1 disc diameter of the centre of the fovea, only if associated with deterioration of best visual acuity to 6 12 or worse. referable pre-proliferative retinopathy (if cotton wool spots are present, look carefully for the following features, but cotton wool spots themselves do not define pre-proliferative retinopathy): any venous beading any venous reduplication any intraretinal microvascular abnormalities multiple deep, round or blot haemorrhages. any large, sudden unexplained drop in visual acuity 2009, amended 2015	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	At the time of publication (March 2017) evidence did not show an increased risk for dapagliflozin and empagliflozin, but the MHRA advised that the risk may be a class effect.	Last updated May 2017	A consultant-led multidisciplinary team may include a wide range of staff based in primary, secondary and community care.	Last updated May 2017	Last updated May 2017	Remember that lesser degrees of weight loss may still be of benefit, and that larger degrees of weight loss in the longer term will have advantageous metabolic impact.	Last updated May 2017	Last updated May 2017 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Last updated May 2017	Last updated May 2017 of the following: quality-controlled plasma glucose profiles total glycated haemoglobin estimation (if abnormal haemoglobins) fructosamine estimation.	Last updated May 2017	Last updated May 2017 hepatic impairment diabetic ketoacidosis current, or a history of, bladder cancer uninvestigated macroscopic haematuria.	Last updated May 2017	Last updated May 2017	Last updated May 2017	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections.	Last updated May 2017 take into account its safety profile, in particular its cardiac risk and potential interactions with other medicines.	Last updated May 2017	Last updated May 2017	Last updated May 2017 circinate or group of exudates within the macula (the macula is defined here as a circle centred on the fovea, with a diameter the distance between the temporal border of the optic disc and the fovea) any microaneurysm or haemorrhage within 1 disc diameter of the centre of the fovea, only if associated with deterioration of best visual acuity to 6 12 or worse. referable pre-proliferative retinopathy (if cotton wool spots are present, look carefully for the following features, but cotton wool spots themselves do not define pre-proliferative retinopathy): any venous beading any venous reduplication any intraretinal microvascular abnormalities multiple deep, round or blot haemorrhages. any large, sudden unexplained drop in visual acuity 2009, amended 2015	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	At the time of publication (March 2017) evidence did not show an increased risk for dapagliflozin and empagliflozin, but the MHRA advised that the risk may be a class effect.	Last updated May 2017	A consultant-led multidisciplinary team may include a wide range of staff based in primary, secondary and community care.	Last updated May 2017	Last updated May 2017 1 Recommendations	Last updated May 2017 annual reinforcement and review	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	Last updated May 2017 the person is pregnant, or is planning to become pregnant	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Treatment with sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some adults with type 2 diabetes if metformin is contraindicated or not tolerated (see NICE's guidance on canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes).	Treatment with combinations of medicines including sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in triple therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	
algorithm	1	0.6892	1	Algorithm for blood glucose lowering therapy in adults with type 2 diabetes	
caution	0	0.6892	8	When prescribing pioglitazone, exercise particular caution if the person is at high risk of the adverse effects of the drug	If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist).	When prescribing pioglitazone, exercise particular caution if the person is at high risk of the adverse effects of the drug	When prescribing pioglitazone, exercise particular caution if the person is at high risk of the adverse effects of the drug	If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist).	When prescribing pioglitazone, exercise particular caution if the person is at high risk of the adverse effects of the drug	Prescribe metformin with caution for those at risk of a sudden deterioration in kidney function and those at risk of eGFR falling below 45 ml minute m2.	Discussions should include precautions for driving.	
filtration	1	0.6892	1	In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute m2:	
ketones	0	0.6892	1	The MHRA advised that healthcare professionals should test for raised ketones in people with ketoacidosis symptoms who are receiving an SGLT-2 inhibitor, even if their plasma glucose levels are near-normal.	
off-label	0	0.6892	1	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2016) warned that serious, life-threatening, and fatal cases of diabetic ketoacidosis have been reported rarely in people taking an SGLT-2 inhibitor (a substantial proportion of the cases concerned off-label use in people with type 1 diabetes, which is not recommended)	
plasma	0	0.6892	5	Last updated May 2017 of the following: quality-controlled plasma glucose profiles total glycated haemoglobin estimation (if abnormal haemoglobins) fructosamine estimation.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	Last updated May 2017 of the following: quality-controlled plasma glucose profiles total glycated haemoglobin estimation (if abnormal haemoglobins) fructosamine estimation.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	The MHRA advised that healthcare professionals should test for raised ketones in people with ketoacidosis symptoms who are receiving an SGLT-2 inhibitor, even if their plasma glucose levels are near-normal.	
prescribe	0	0.6892	6	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Prescribe metformin with caution for those at risk of a sudden deterioration in kidney function and those at risk of eGFR falling below 45 ml minute m2.	For adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that: there is not strong evidence that any available antiemetic therapy is effective some people have had benefit with domperidone , erythromycin or metoclopramide . the strongest evidence for effectiveness is for domperidone , but prescribers must	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	The MHRA advises that prescribers should take into account the overall safety profile of domperidone, and in particular its cardiac risk and potential interactions with other medicines (such as erythromycin), if there is a clinical need to use it at doses or durations greater than those authorised	The prescriber should follow relevant professional guidance, taking full responsibility for the decision	
professionals	0	0.6892	1	The MHRA advised that healthcare professionals should test for raised ketones in people with ketoacidosis symptoms who are receiving an SGLT-2 inhibitor, even if their plasma glucose levels are near-normal.	
proportion	1	0.6892	1	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2016) warned that serious, life-threatening, and fatal cases of diabetic ketoacidosis have been reported rarely in people taking an SGLT-2 inhibitor (a substantial proportion of the cases concerned off-label use in people with type 1 diabetes, which is not recommended)	
rate	1	0.6892	23	Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight.	HbA1c is 75 mmol mol  percent or higher), administered either: separately or as a pre-mixed (biphasic) human insulin preparation.	HbA1c reached or who cannot use the device needed to inject NPH insulin but who could administer their own insulin safely and accurately if a switch to one of the long-acting insulin analogues was made or	In several cases, blood glucose levels were only moderately elevated	Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight.	HbA1c is 75 mmol mol  percent or higher), administered either: separately or as a pre-mixed (biphasic) human insulin preparation.	HbA1c reached or who cannot use the device needed to inject NPH insulin but who could administer their own insulin safely and accurately if a switch to one of the long-acting insulin analogues was made or	In several cases, blood glucose levels were only moderately elevated	Be aware that, if metformin is contraindicated or not tolerated, repaglinide is both clinically effective and cost effective in adults with type 2 diabetes	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	Encourage high-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids.	Individualise recommendations for carbohydrate and alcohol intake, and meal patterns	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks.	Use methods to measure HbA1c that have been calibrated according to	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute m2:	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea.	Treatment with sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some adults with type 2 diabetes if metformin is contraindicated or not tolerated (see NICE's guidance on canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes).	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations – ).	Be aware that, if metformin is contraindicated or not tolerated, repaglinide is both clinically effective and cost effective in adults with type 2 diabetes	
implications	0	0.687	1	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	
m2and	0	0.687	1	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	
minority	1	0.687	1	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	
intolerance	0	0.6866	3	For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor.	For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor.	When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance	
point	0	0.6866	1	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
technique	0	0.6866	1	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
telephone	0	0.6866	1	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
understanding	0	0.6866	3	It is delivered by trained educators who have an understanding of educational theory appropriate to the age and needs of the person, and who are trained and competent to deliver the principles and content of the programme.	It is delivered by trained educators who have an understanding of educational theory appropriate to the age and needs of the person, and who are trained and competent to deliver the principles and content of the programme.	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
glucose	0	0.6848	32	Blood glucose management	If HbA1c monitoring is invalid because of disturbed erythrocyte turnover or abnormal haemoglobin type, estimate trends in blood glucose control using one	Last updated May 2017 of the following: quality-controlled plasma glucose profiles total glycated haemoglobin estimation (if abnormal haemoglobins) fructosamine estimation.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	In several cases, blood glucose levels were only moderately elevated	Blood glucose management	If HbA1c monitoring is invalid because of disturbed erythrocyte turnover or abnormal haemoglobin type, estimate trends in blood glucose control using one	Last updated May 2017 of the following: quality-controlled plasma glucose profiles total glycated haemoglobin estimation (if abnormal haemoglobins) fructosamine estimation.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	In several cases, blood glucose levels were only moderately elevated	Treatment with a single non-insulin blood glucose lowering therapy (monotherapy)	Treatment with 2 non-insulin blood glucose lowering therapies in combination (dual therapy)	Treatment with either 3 non-insulin blood glucose lowering therapies in combination (triple therapy) or any treatment combination containing insulin	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	Investigate unexplained discrepancies between HbA1c and other glucose measurements	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	Self-monitoring of blood glucose	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia.	If adults with type 2 diabetes are self-monitoring their blood glucose levels, carry out a structured assessment at least annually	The assessment should include: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used.	If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations – ) or a sulfonylurea, and review treatment when blood glucose control has been achieved.	Algorithm for blood glucose lowering therapy in adults with type 2 diabetes	Treatment with sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some adults with type 2 diabetes if metformin is contraindicated or not tolerated (see NICE's guidance on canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes).	Treatment with combinations of medicines including sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Review the continued need for other blood glucose lowering therapies .	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if: the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs.	Consider pre-mixed (biphasic) preparations that include short-acting insulin analogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals.	Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015	The MHRA advised that healthcare professionals should test for raised ketones in people with ketoacidosis symptoms who are receiving an SGLT-2 inhibitor, even if their plasma glucose levels are near-normal.	
detemir	1	0.673	4	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if: the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs.	Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	
guidance	1	0.6489	32	The following guidance is based on the best available evidence	The full guideline gives details of the methods and the evidence used to develop the guidance.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2014) notes that domperidone is associated with a small increased risk of serious cardiac side effects	MHRA guidance and summaries of product characteristics	See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.	The following guidance is based on the best available evidence	The full guideline gives details of the methods and the evidence used to develop the guidance.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2014) notes that domperidone is associated with a small increased risk of serious cardiac side effects	MHRA guidance and summaries of product characteristics	See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy.	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Treatment with sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some adults with type 2 diabetes if metformin is contraindicated or not tolerated (see NICE's guidance on canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes).	Treatment with combinations of medicines including sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in triple therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	For guidance on insulin delivery for adults with type 2 diabetes, see the insulin delivery section in the NICE guideline on type 1 diabetes.	For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance.	For guidance on managing painful diabetic peripheral neuropathy in adults with type 2 diabetes, see the NICE guideline on neuropathic pain in adults.	For guidance on preventing and managing foot problems in adults with type 2 diabetes, see the NICE guideline on diabetic foot problems.	For guidance on managing kidney disease in adults with type 2 diabetes, see the	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2016) warned that serious, life-threatening, and fatal cases of diabetic ketoacidosis have been reported rarely in people taking an SGLT-2 inhibitor (a substantial proportion of the cases concerned off-label use in people with type 1 diabetes, which is not recommended)	The prescriber should follow relevant professional guidance, taking full responsibility for the decision	
combinations	0	0.6427	4	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Treatment with combinations of medicines including sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in triple therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	
nice	1	0.6366	16	For more information about supporting adherence, see the NICE guideline on medicines adherence.	For more information about supporting adherence, see the NICE guideline on medicines adherence.	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	Provide lifestyle advice (see section in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy.	For more information, see the NICE guideline on diabetes in pregnancy.	Treatment with sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some adults with type 2 diabetes if metformin is contraindicated or not tolerated (see NICE's guidance on canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes).	Treatment with combinations of medicines including sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in triple therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	For guidance on insulin delivery for adults with type 2 diabetes, see the insulin delivery section in the NICE guideline on type 1 diabetes.	For guidance on managing painful diabetic peripheral neuropathy in adults with type 2 diabetes, see the NICE guideline on neuropathic pain in adults.	For guidance on preventing and managing foot problems in adults with type 2 diabetes, see the NICE guideline on diabetic foot problems.	NICE guideline on chronic kidney disease in adults.	
bolus	1	0.6263	1	Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	
change	1	0.6263	5	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life.	Make changes only if there is poor control or if current drug treatment is not appropriate because of microvascular complications or metabolic problems.	Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	
monitor	0	0.6224	14	Monitor the blood pressure of a person who has attained and consistently remained at his or her blood pressure target every 4–6 months	If HbA1c monitoring is invalid because of disturbed erythrocyte turnover or abnormal haemoglobin type, estimate trends in blood glucose control using one	Monitor the blood pressure of a person who has attained and consistently remained at his or her blood pressure target every 4–6 months	If HbA1c monitoring is invalid because of disturbed erythrocyte turnover or abnormal haemoglobin type, estimate trends in blood glucose control using one	Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	Self-monitoring of blood glucose	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia.	If adults with type 2 diabetes are self-monitoring their blood glucose levels, carry out a structured assessment at least annually	The assessment should include: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used.	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	
accordance	0	0.6056	3	Refer to an ophthalmologist in accordance with the National Screening	Refer to an ophthalmologist in accordance with the National Screening	For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance.	
erythomycin	0	0.6056	1	For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance.	
month	0	0.6015	11	Monitor the blood pressure of a person who has attained and consistently remained at his or her blood pressure target every 4–6 months	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).	Perform screening as soon as possible and no later than 3 months from referral	Monitor the blood pressure of a person who has attained and consistently remained at his or her blood pressure target every 4–6 months	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).	Perform screening as soon as possible and no later than 3 months from referral	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage.	Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage).	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	
repeat	1	0.6015	4	Arrange repeat structured eye screening annually. 2009, amended 2016	Arrange repeat structured eye screening annually. 2009, amended 2016	Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage.	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	
need	1	0.5922	22	It is evidence-based, and suits the needs of the person.	It is delivered by trained educators who have an understanding of educational theory appropriate to the age and needs of the person, and who are trained and competent to deliver the principles and content of the programme.	Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area.	Offer NPH insulin injected once or twice daily according to need.	HbA1c reached or who cannot use the device needed to inject NPH insulin but who could administer their own insulin safely and accurately if a switch to one of the long-acting insulin analogues was made or	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections.	It is evidence-based, and suits the needs of the person.	It is delivered by trained educators who have an understanding of educational theory appropriate to the age and needs of the person, and who are trained and competent to deliver the principles and content of the programme.	Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area.	Offer NPH insulin injected once or twice daily according to need.	HbA1c reached or who cannot use the device needed to inject NPH insulin but who could administer their own insulin safely and accurately if a switch to one of the long-acting insulin analogues was made or	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections.	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	Reassess the person's needs and circumstances at each review and think about whether to stop any medicines that are not effective.	Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life.	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Review the continued need for other blood glucose lowering therapies .	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if: the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs.	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	The MHRA advises that prescribers should take into account the overall safety profile of domperidone, and in particular its cardiac risk and potential interactions with other medicines (such as erythromycin), if there is a clinical need to use it at doses or durations greater than those authorised	
analogues	1	0.5727	5	HbA1c reached or who cannot use the device needed to inject NPH insulin but who could administer their own insulin safely and accurately if a switch to one of the long-acting insulin analogues was made or	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections.	HbA1c reached or who cannot use the device needed to inject NPH insulin but who could administer their own insulin safely and accurately if a switch to one of the long-acting insulin analogues was made or	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections.	Consider pre-mixed (biphasic) preparations that include short-acting insulin analogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals.	
problem	0	0.5727	9	Diabetic foot problems	Diabetic foot problems	Make changes only if there is poor control or if current drug treatment is not appropriate because of microvascular complications or metabolic problems.	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	Consider pre-mixed (biphasic) preparations that include short-acting insulin analogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals.	Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems.	For guidance on preventing and managing foot problems in adults with type 2 diabetes, see the NICE guideline on diabetic foot problems.	Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options.	Consider a phosphodiesterase-5 inhibitor to treat problematic erectile dysfunction in men with type 2 diabetes, initially choosing the drug with the lowest acquisition cost and taking into account any contraindications.	
frequency	0	0.5701	2	The assessment should include: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used.	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if: the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs.	
activity	0	0.5569	3	Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight.	Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight.	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	
harm	1	0.5569	3	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	
health	1	0.5569	20	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2014) notes that domperidone is associated with a small increased risk of serious cardiac side effects	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) notes that cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of cardiac failure	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2014) notes that domperidone is associated with a small increased risk of serious cardiac side effects	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition.	Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if: the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'.	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2016) warned that serious, life-threatening, and fatal cases of diabetic ketoacidosis have been reported rarely in people taking an SGLT-2 inhibitor (a substantial proportion of the cases concerned off-label use in people with type 1 diabetes, which is not recommended)	The MHRA advised that healthcare professionals should test for raised ketones in people with ketoacidosis symptoms who are receiving an SGLT-2 inhibitor, even if their plasma glucose levels are near-normal.	
maternity	0	0.5569	1	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	
reduction	0	0.5569	4	Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	
referrals	0	0.5569	1	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	
comorbidities	0	0.554	4	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	
polypharmacy	0	0.5365	2	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	
preferences	1	0.5365	2	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	
benefits	0	0.5314	2	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	For adults with type 2 diabetes, discuss the benefits and risks of drug treatment, and the options available	
expectancy	0	0.5266	2	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	
regimen	0	0.526	3	Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	
base	1	0.5196	14	The following guidance is based on the best available evidence	It is evidence-based, and suits the needs of the person.	It has a structured curriculum that is theory-driven, evidence-based and resource-effective, has supporting materials, and is written down.	A consultant-led multidisciplinary team may include a wide range of staff based in primary, secondary and community care.	The following guidance is based on the best available evidence	It is evidence-based, and suits the needs of the person.	It has a structured curriculum that is theory-driven, evidence-based and resource-effective, has supporting materials, and is written down.	A consultant-led multidisciplinary team may include a wide range of staff based in primary, secondary and community care.	However, discuss with any person for whom repaglinide is being considered, that there is no licensed non-metformin-based combination containing repaglinide that can be offered at first intensification.	Base the choice of drug treatment(s) on: the effectiveness of the drug treatment(s) in terms of metabolic response	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations – ).	Insulin-based treatments	However, discuss with any person for whom repaglinide is being considered, that there is no licensed non-metformin-based combination containing repaglinide that can be offered at first intensification.	
indications	0	0.5196	3	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance	Consider a phosphodiesterase-5 inhibitor to treat problematic erectile dysfunction in men with type 2 diabetes, initially choosing the drug with the lowest acquisition cost and taking into account any contraindications.	
option	0	0.5196	5	Offer group education programmes as the preferred option	Offer group education programmes as the preferred option	For adults with type 2 diabetes, discuss the benefits and risks of drug treatment, and the options available	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options.	
response	1	0.5196	3	Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	Base the choice of drug treatment(s) on: the effectiveness of the drug treatment(s) in terms of metabolic response	
terms	0	0.5196	3	Terms used in this guideline	Terms used in this guideline	Base the choice of drug treatment(s) on: the effectiveness of the drug treatment(s) in terms of metabolic response	
conditions	1	0.5159	24	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Known risk factors for these conditions, including increased age, should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	
ability	0	0.5118	3	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	Last updated May 2017 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost).	Be aware that the drugs in dual therapy should be introduced in a stepwise manner, checking for tolerability and effectiveness of each drug.	
approach	1	0.5118	3	Such an approach is especially important in the context of multimorbidity.	Such an approach is especially important in the context of multimorbidity.	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	
certainty	0	0.5118	1	The wording used in the recommendations in this guideline (for example, words such as 'offer' and 'consider') denotes the certainty with which the recommendation is made (the strength of the recommendation)	
monotherapy	0	0.5118	1	Treatment with a single non-insulin blood glucose lowering therapy (monotherapy)	
strength	0	0.5118	1	The wording used in the recommendations in this guideline (for example, words such as 'offer' and 'consider') denotes the certainty with which the recommendation is made (the strength of the recommendation)	
wording	0	0.5118	1	The wording used in the recommendations in this guideline (for example, words such as 'offer' and 'consider') denotes the certainty with which the recommendation is made (the strength of the recommendation)	
words	0	0.5118	1	The wording used in the recommendations in this guideline (for example, words such as 'offer' and 'consider') denotes the certainty with which the recommendation is made (the strength of the recommendation)	
ng28	0	0.5072	22	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	
notice-of-rights	0	0.5072	22	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	
awareness	0	0.5031	1	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	
basis	1	0.5031	1	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	
consequences	0	0.5031	1	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	
consideration	0	0.5031	1	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	
job	0	0.5031	1	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	
risk-reduction	0	0.5031	1	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	
management	0	0.498	33	Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight.	Blood pressure management	Blood glucose management	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight.	Blood pressure management	Blood glucose management	DVLA guidance (At a glance guide to the current medical standards of fitness to drive) management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Following discussion, refer men with type 2 diabetes to a service offering other medical, surgical or psychological management of erectile dysfunction if treatment (including a phosphodiesterase-5 inhibitor, as appropriate) has been unsuccessful.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	
choice	1	0.449	2	Base the choice of drug treatment(s) on: the effectiveness of the drug treatment(s) in terms of metabolic response	Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:	
preparation	0	0.3651	4	HbA1c is 75 mmol mol  percent or higher), administered either: separately or as a pre-mixed (biphasic) human insulin preparation.	HbA1c is 75 mmol mol  percent or higher), administered either: separately or as a pre-mixed (biphasic) human insulin preparation.	Consider pre-mixed (biphasic) preparations that include short-acting insulin analogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals.	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	
assistance	1	0.3554	1	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if: the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs.	
carer	0	0.3554	7	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections.	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections.	Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with	Explain to people and their carers that structured education is an integral part of diabetes care.	It has specific aims and learning objectives, and supports the person and their family members and carers in developing attitudes, beliefs, knowledge and skills to self-manage diabetes.	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if: the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs.	
glucose-lowering	0	0.3554	1	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if: the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs.	
number	1	0.3554	3	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections.	Last updated May 2017 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections.	Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:	
regimens	0	0.3554	1	Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:	
short-acting	0	0.3554	4	Consider starting both NPH and short-acting insulin (particularly if the person's	Consider pre-mixed (biphasic) preparations that include short-acting insulin analogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals.	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	
start	1	0.3554	6	Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia.	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance	Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:	Consider starting both NPH and short-acting insulin (particularly if the person's	
types	0	0.3554	1	Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:	
adults	1	0.3178	83	Be aware that, if metformin is contraindicated or not tolerated, repaglinide is both clinically effective and cost effective in adults with type 2 diabetes	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	Take into account any disabilities, including visual impairment, when planning and delivering care for adults with type 2 diabetes.	Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Ensure that any structured education programme for adults with type 2 diabetes includes the following components:	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes	For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks.	Provide lifestyle advice (see section in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease.	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Involve adults with type 2 diabetes in decisions about their individual HbA1c target	Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section )	For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol ( percent)	For adults on a drug associated with hypoglycaemia, support the person to aim for an HbA1c level of 53 mmol mol ( percent).	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia.	Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia	If adults with type 2 diabetes are self-monitoring their blood glucose levels, carry out a structured assessment at least annually	For adults with type 2 diabetes, discuss the benefits and risks of drug treatment, and the options available	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes.	Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes.	Algorithm for blood glucose lowering therapy in adults with type 2 diabetes	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute m2:	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea.	In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Treatment with sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some adults with type 2 diabetes if metformin is contraindicated or not tolerated (see NICE's guidance on canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes).	In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations – ).	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team .	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance	Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	For guidance on insulin delivery for adults with type 2 diabetes, see the insulin delivery section in the NICE guideline on type 1 diabetes.	Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015	For adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that: there is not strong evidence that any available antiemetic therapy is effective some people have had benefit with domperidone , erythromycin or metoclopramide . the strongest evidence for effectiveness is for domperidone , but prescribers must	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance.	For guidance on managing painful diabetic peripheral neuropathy in adults with type 2 diabetes, see the NICE guideline on neuropathic pain in adults.	Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015	Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015	When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension.	Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	For guidance on preventing and managing foot problems in adults with type 2 diabetes, see the NICE guideline on diabetic foot problems.	For guidance on managing kidney disease in adults with type 2 diabetes, see the	NICE guideline on chronic kidney disease in adults.	On diagnosis, GPs should immediately refer adults with type 2 diabetes to the local eye screening service	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Explain the reasons for, and success of, eye screening systems to adults with type 2 diabetes, so that attendance is not reduced by lack of knowledge or fear of outcome.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Be aware that, if metformin is contraindicated or not tolerated, repaglinide is both clinically effective and cost effective in adults with type 2 diabetes	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	
diabetes	1	0.2068	107	Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight.	Discourage the use of foods marketed specifically for people with diabetes.	Seek advice from a team with specialist expertise in diabetes or clinical biochemistry.	Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight.	Discourage the use of foods marketed specifically for people with diabetes.	Seek advice from a team with specialist expertise in diabetes or clinical biochemistry.	Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	Be aware that, if metformin is contraindicated or not tolerated, repaglinide is both clinically effective and cost effective in adults with type 2 diabetes	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	Take into account any disabilities, including visual impairment, when planning and delivering care for adults with type 2 diabetes.	Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Explain to people and their carers that structured education is an integral part of diabetes care.	Ensure that any structured education programme for adults with type 2 diabetes includes the following components:	It has specific aims and learning objectives, and supports the person and their family members and carers in developing attitudes, beliefs, knowledge and skills to self-manage diabetes.	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes	For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks.	For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease	For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease.	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Involve adults with type 2 diabetes in decisions about their individual HbA1c target	Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section )	For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol ( percent)	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it	For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy.	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	For more information, see the NICE guideline on diabetes in pregnancy.	Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia.	Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia	If adults with type 2 diabetes are self-monitoring their blood glucose levels, carry out a structured assessment at least annually	For adults with type 2 diabetes, discuss the benefits and risks of drug treatment, and the options available	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations – ) or a sulfonylurea, and review treatment when blood glucose control has been achieved.	Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes.	Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes.	If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin.	Algorithm for blood glucose lowering therapy in adults with type 2 diabetes	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute m2:	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea.	In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Treatment with sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some adults with type 2 diabetes if metformin is contraindicated or not tolerated (see NICE's guidance on canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes).	In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	Treatment with combinations of medicines including sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations – ).	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team .	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in triple therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance	Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	For guidance on insulin delivery for adults with type 2 diabetes, see the insulin delivery section in the NICE guideline on type 1 diabetes.	Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015	For adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that: there is not strong evidence that any available antiemetic therapy is effective some people have had benefit with domperidone , erythromycin or metoclopramide . the strongest evidence for effectiveness is for domperidone , but prescribers must	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance.	For guidance on managing painful diabetic peripheral neuropathy in adults with type 2 diabetes, see the NICE guideline on neuropathic pain in adults.	Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015	Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015	When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension.	Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	For guidance on preventing and managing foot problems in adults with type 2 diabetes, see the NICE guideline on diabetic foot problems.	For guidance on managing kidney disease in adults with type 2 diabetes, see the	Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review.	Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options.	Consider a phosphodiesterase-5 inhibitor to treat problematic erectile dysfunction in men with type 2 diabetes, initially choosing the drug with the lowest acquisition cost and taking into account any contraindications.	Following discussion, refer men with type 2 diabetes to a service offering other medical, surgical or psychological management of erectile dysfunction if treatment (including a phosphodiesterase-5 inhibitor, as appropriate) has been unsuccessful.	On diagnosis, GPs should immediately refer adults with type 2 diabetes to the local eye screening service	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Explain the reasons for, and success of, eye screening systems to adults with type 2 diabetes, so that attendance is not reduced by lack of knowledge or fear of outcome.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Be aware that, if metformin is contraindicated or not tolerated, repaglinide is both clinically effective and cost effective in adults with type 2 diabetes	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2016) warned that serious, life-threatening, and fatal cases of diabetic ketoacidosis have been reported rarely in people taking an SGLT-2 inhibitor (a substantial proportion of the cases concerned off-label use in people with type 1 diabetes, which is not recommended)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	
type	0	0.1948	100	If HbA1c monitoring is invalid because of disturbed erythrocyte turnover or abnormal haemoglobin type, estimate trends in blood glucose control using one	Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	If HbA1c monitoring is invalid because of disturbed erythrocyte turnover or abnormal haemoglobin type, estimate trends in blood glucose control using one	Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol  percent in	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2017) warned that canagliflozin may increase the risk of lower-limb amputation (mainly toes) in people with type 2 diabetes	Be aware that, if metformin is contraindicated or not tolerated, repaglinide is both clinically effective and cost effective in adults with type 2 diabetes	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy.	Take into account any disabilities, including visual impairment, when planning and delivering care for adults with type 2 diabetes.	Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Ensure that any structured education programme for adults with type 2 diabetes includes the following components:	Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes	For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent	Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks.	For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity.	Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease	For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease.	For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction.	In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Involve adults with type 2 diabetes in decisions about their individual HbA1c target	Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section )	For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol ( percent)	In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol ( percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol ( percent) and intensify drug treatment.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Last updated May 2017 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities.	If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it	For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy.	Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes.	Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia.	Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia	If adults with type 2 diabetes are self-monitoring their blood glucose levels, carry out a structured assessment at least annually	For adults with type 2 diabetes, discuss the benefits and risks of drug treatment, and the options available	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations – ) or a sulfonylurea, and review treatment when blood glucose control has been achieved.	Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes.	Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes.	If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin.	Algorithm for blood glucose lowering therapy in adults with type 2 diabetes	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute m2:	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea.	In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Treatment with sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some adults with type 2 diabetes if metformin is contraindicated or not tolerated (see NICE's guidance on canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes).	In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea.	Treatment with combinations of medicines including sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations – ).	If triple therapy with metformin and 2 other oral drugs (see recommendation ) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities.	In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation ) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations – ).	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team .	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in triple therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding	When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance	Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation).	Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate.	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes.	For guidance on insulin delivery for adults with type 2 diabetes, see the insulin delivery section in the NICE guideline on type 1 diabetes.	Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015	For adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that: there is not strong evidence that any available antiemetic therapy is effective some people have had benefit with domperidone , erythromycin or metoclopramide . the strongest evidence for effectiveness is for domperidone , but prescribers must	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance.	For guidance on managing painful diabetic peripheral neuropathy in adults with type 2 diabetes, see the NICE guideline on neuropathic pain in adults.	Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015	Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015	When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension.	Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	For guidance on preventing and managing foot problems in adults with type 2 diabetes, see the NICE guideline on diabetic foot problems.	For guidance on managing kidney disease in adults with type 2 diabetes, see the	Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review.	Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options.	Consider a phosphodiesterase-5 inhibitor to treat problematic erectile dysfunction in men with type 2 diabetes, initially choosing the drug with the lowest acquisition cost and taking into account any contraindications.	Following discussion, refer men with type 2 diabetes to a service offering other medical, surgical or psychological management of erectile dysfunction if treatment (including a phosphodiesterase-5 inhibitor, as appropriate) has been unsuccessful.	On diagnosis, GPs should immediately refer adults with type 2 diabetes to the local eye screening service	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Explain the reasons for, and success of, eye screening systems to adults with type 2 diabetes, so that attendance is not reduced by lack of knowledge or fear of outcome.	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Be aware that, if metformin is contraindicated or not tolerated, repaglinide is both clinically effective and cost effective in adults with type 2 diabetes	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	Medicines and Healthcare products Regulatory Agency (MHRA) guidance (2016) warned that serious, life-threatening, and fatal cases of diabetic ketoacidosis have been reported rarely in people taking an SGLT-2 inhibitor (a substantial proportion of the cases concerned off-label use in people with type 1 diabetes, which is not recommended)	Type 2 diabetes in adults: management (NG28) conditions notice-of-rights)	
